Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Page Path
HOME > Browse
13
Filter
Filter
Keywords
Original Articles
COVID-19
Association of Metabolic Syndrome with COVID-19 in the Republic of Korea
Woo-Hwi Jeon, Jeong-Yeon Seon, So-Youn Park, In-Hwan Oh
Diabetes Metab J. 2022;46(3):427-438.   Published online November 26, 2021
DOI: https://doi.org/10.4093/dmj.2021.0105
  • 4,218 View
  • 241 Download
  • 2 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Metabolic syndrome (MetS) is reportedly a crucial risk factor for coronavirus disease 2019 (COVID-19). Since the epidemiological studies that examine this association are few and include small samples, we investigated the relationship between MetS and COVID-19 severity and death using a larger sample in the Republic of Korea.
Methods
We analyzed 66,321 patients, 4,066 of whom had COVID-19. We used chi-square tests to examine patients’ characteristics. We performed logistic regression analysis to analyze differences in COVID-19 infection and clinical outcomes according to the presence of MetS.
Results
Although MetS was not significantly associated with COVID-19 risk, acquiring MetS was significantly associated with the risk of severe COVID-19 outcomes (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.34 to 2.91; P=0.001). The mortality risk was significantly higher in COVID-19 patients with MetS (OR, 1.74; 95% CI, 1.17 to 2.59; P=0.006). Patients with abnormal waist circumference were approximately 2.07 times more likely to develop severe COVID-19 (P<0.001), and high-density lipoprotein cholesterol (HDL-C) levels were significantly associated with COVID-19; the mortality risk due to COVID-19 was 1.74 times higher in men with an HDL-C level of <40 mg/dL and in women with an HDL-C level of <50 mg/dL (P=0.012).
Conclusion
COVID-19 is likely associated with severity and death in patients with MetS or in patients with MetS risk factors. Therefore, patients with MetS or those with abnormal waist circumference and HDL-C levels need to be treated with caution.

Citations

Citations to this article as recorded by  
  • Heterogeneity in familial clustering of metabolic syndrome components in the multiethnic GENNID study
    Jia Y. Wan, Deborah Goodman, Sukh Makhnoon, Trina M. Norden‐Krichmar, Baolin Wu, Karen L. Edwards
    Obesity.2024; 32(1): 176.     CrossRef
  • Associated Factors with Changes of Metabolic Abnormalities among General Population in COVID-19 Pandemic
    Eunjoo Kwon, Eun-Hee Nah, Suyoung Kim, Seon Cho, Hyeran Park
    Korean Journal of Health Promotion.2023; 23(2): 55.     CrossRef
  • Association between metabolic syndrome and mortality in patients with COVID-19: A nationwide cohort study
    Hyo Jin Park, Jin-Hyung Jung, Kyungdo Han, Jean Shin, Yoojeong Lee, Yujin Chang, Kyeyeung Park, Yoon Jeong Cho, Youn Seon Choi, Seon Mee Kim, Ga Eun Nam
    Obesity Research & Clinical Practice.2022; 16(6): 484.     CrossRef
COVID-19
Impact of COVID-19 Lockdown on the Metabolic Control Parameters in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
Ifan Ali Wafa, Nando Reza Pratama, Nurizzah Farahiyah Sofia, Elsha Stephanie Anastasia, Tiffany Konstantin, Maharani Ayuputeri Wijaya, M. Rifqi Wiyono, Lilik Djuari, Hermina Novida
Diabetes Metab J. 2022;46(2):260-272.   Published online March 8, 2022
DOI: https://doi.org/10.4093/dmj.2021.0125
  • 5,358 View
  • 270 Download
  • 8 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Abrupt implementation of lockdowns during the coronavirus disease 2019 (COVID-19) pandemic affected the management of diabetes mellitus in patients worldwide. Limited access to health facilities and lifestyle changes potentially affected metabolic parameters in patients at risk. We conducted a meta-analysis to determine any differences in the control of metabolic parameters in patients with diabetes, before and during lockdown.
Methods
We performed searches of five databases. Meta-analyses were carried out using random- or fixed-effect approaches to glycaemic control parameters as the primary outcome: glycosylated hemoglobin (HbA1c), random blood glucose (RBG), fasting blood glucose (FBG), time-in-range (TIR), time-above-range (TAR), time-below-range (TBR). Mean difference (MD), confidence interval (CI), and P value were calculated. Lipid profile was a secondary outcome and is presented as a descriptive analysis.
Results
Twenty-one studies enrolling a total of 3,992 patients with type 1 or type 2 diabetes mellitus (T1DM or T2DM) were included in the study. Patients with T1DM showed a significant improvement of TIR and TAR (MD=3.52% [95% CI, 0.29 to 6.74], I2=76%, P=0.03; MD=–3.36% [95% CI, –6.48 to –0.25], I2=75%, P=0.03), while FBG among patients with T2DM significantly worsened (MD=3.47 mg/dL [95% CI, 1.22 to 5.73], I2=0%, P<0.01). No significant difference was found in HbA1c, RBG, and TBR. Use of continuous glucose monitoring in T1DM facilitated good glycaemic control. Significant deterioration of lipid parameters during lockdown, particularly triglyceride, was observed.
Conclusion
Implementation of lockdowns during the COVID-19 pandemic did not worsen glycaemic control in patients with diabetes. Other metabolic parameters improved during lockdown, though lipid parameters, particularly triglyceride, worsened.

Citations

Citations to this article as recorded by  
  • Disruption of diabetes and hypertension care during the COVID-19 pandemic and recovery approaches in the Latin America and Caribbean region: a scoping review protocol
    Samira Barbara Jabakhanji, Oluwabunmi Ogungbe, Sonia Y Angell, Lawrence Appel, David Byrne, Roopa Mehta, John McCaffrey, Lori Rosman, Edward W Gregg, Kunihiro Matsushita
    BMJ Open.2024; 14(1): e074443.     CrossRef
  • Glycemic Control in Type 1 Diabetes Mellitus and COVID-19: What We Learned From the Lockdown Experience
    Catarina Almeida, André Ferreira, Daniela Duarte, Ana Filipa Viegas, André Santos, Alexandra Vaz, Edite Nascimento
    Cureus.2023;[Epub]     CrossRef
  • Changes in body weight and glycemic control in association with COVID-19 Shutdown among 23,000 adults with type 2 diabetes
    Emily Panza, Kevin E. Kip, Kripa Venkatakrishnan, Oscar C. Marroquin, Rena R. Wing
    Acta Diabetologica.2023; 60(6): 787.     CrossRef
  • The Impact of a Lockdown for the COVID-19 Pandemic on Seasonal HbA1c Variation in Patients with Type 2 Diabetes
    Yu-Cheng Cheng, Yu-Hsuan Li, Hsiu-Chen Liu, Chiann-Yi Hsu, Wan-Jen Chang, I-Te Lee, Chin-Li Lu
    Life.2023; 13(3): 763.     CrossRef
  • The Impact of Partial Lockdown During COVID-19 Pandemic on Metabolic Control in People with Type 2 Diabetes Mellitus
    Ayşe Zülal TOKAÇ, Tuğde Buse UĞUR, Buse Ecem KURUGÖL, Sevilay ALİGÜLÜ, Osman HAYRAN
    Journal of Biotechnology and Strategic Health Research.2023; 7(1): 67.     CrossRef
  • Retrospective Study on the Impact of COVID-19 Lockdown on Patients with Type 2 Diabetes in Northern Taiwan
    Hsuan Huang, Hsiao-Ling Su, Chih-Hsung Huang, Yi-Hsin Lin
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2539.     CrossRef
  • RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications
    Dan Ke, Zhen Zhang, Jieting Liu, Peijian Chen, Yucen Dai, Xinhai Sun, Yanhui Chu, Luxin Li
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • “Does Physical Exercise Promote Health Benefits for Diabetic Patients during the COVID-19 Pandemic?”: A Systematic Review
    Erivaldo de Souza, Daniela Meneses-Santos, Josué Cruz Santos, Felipe J. Aidar, Carla Roberta de Oliveira Carvalho, Jymmys Lopes dos Santos, Anderson Carlos Marçal
    Sports.2023; 11(10): 192.     CrossRef
  • Impact of National Lockdown From COVID-19 Pandemic in Patients With Type 2 Diabetes: An Observational Study
    Nuntakorn Thongtang, Niracha Chanwimol, Lukana Preechasuk, Varisara Boonyuang, Pinyo Rattanaumpawan, Supawadee Likitmaskul, Apiradee Sriwijitkamol
    Asia Pacific Journal of Public Health.2022; 34(6-7): 708.     CrossRef
COVID-19
Effects of Social Distancing on Diabetes Management in Older Adults during COVID-19 Pandemic
Soo Myoung Shin, Tae Jung Oh, Sung Hee Choi, Hak Chul Jang
Diabetes Metab J. 2021;45(5):765-772.   Published online August 30, 2021
DOI: https://doi.org/10.4093/dmj.2021.0096
  • 5,795 View
  • 189 Download
  • 9 Web of Science
  • 9 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
On March 22, 2020, intense social distancing (SD) was implemented in Korea to prevent the spread of coronavirus disease 19 (COVID-19). This study examined the impact of SD on diabetes control in older adults with diabetes.
Methods
Adults aged 60 to 90 years with type 2 diabetes mellitus who were physically and mentally independent were recruited. Participants who had complete blood chemistry data from April to July 2019 (pre-SD era) and April to July 2020 (SD era) were enrolled. Data were obtained about physical activity, nutrition, sarcopenia, and psychological and mental health from questionnaires in April to July 2020. Calf circumference was measured.
Results
In total, 246 people (100 men, 146 women; mean age, 73.8±5.7 years) participated in this study. The levels of glycated hemoglobin (HbA1c, 7.4%±1.0% vs. 7.1%±0.8%, P<0.001), fasting glucose (142.2±16.7 mg/dL vs. 132.0±27.7 mg/dL, P<0.001), and body weight (62.6±9.4 kg vs. 61.8±10.1 kg, P<0.01) were higher in the SD era than in the pre-SD era. Total physical activity was lower in the SD era (2,584.6±2,624.1 MET-min/week–1 vs. 1,987.3±2,295.0 MET-min/week–1, P<0.001). A larger increase in HbA1c level was associated with increased body weight and decreased physical activity.
Conclusion
SD had negative effects on diabetes management in older adults with diabetes. Fasting glucose and HbA1c levels and body weight increased during the SD era. Participants with reduced physical activity gained more weight and had higher blood glucose levels. Given that the COVID-19 pandemic is ongoing, health professionals and diabetes educators should monitor changes in lifestyle factors in older adults with diabetes.

Citations

Citations to this article as recorded by  
  • Preliminary efficacy of a technology-based physical activity intervention for older Korean adults during the COVID-19 pandemic
    Soonhyung Kwon, Oejin Shin, Rosalba Hernandez
    Educational Gerontology.2024; 50(1): 27.     CrossRef
  • Obesity and weight change during the COVID‐19 pandemic in children and adults: A systematic review and meta‐analysis
    Laura N. Anderson, Yulika Yoshida‐Montezuma, Nora Dewart, Ezza Jalil, Jayati Khattar, Vanessa De Rubeis, Sarah Carsley, Lauren E. Griffith, Lawrence Mbuagbaw
    Obesity Reviews.2023;[Epub]     CrossRef
  • Changes in lifestyle-related behaviour during the COVID-19 pandemic in Japan: a questionnaire survey for examinees who underwent an annual health check-up
    Miyako Kishimoto, Kayo Masuko, Sumie Yamamoto, Retsu Fujita, Shoko Nakamura, Masato Odawara, Mikio Zeniya
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Glycaemic monitoring and control among high-risk patients with type 2 diabetes in Australian general practice during COVID-19
    Kirrilee Jane Barlow, Paul P Fahey, Evan Atlantis
    Family Medicine and Community Health.2023; 11(3): e002271.     CrossRef
  • Social isolation, loneliness and subsequent risk of major adverse cardiovascular events among individuals with type 2 diabetes mellitus
    Yannis Yan Liang, Yilin Chen, Hongliang Feng, Huachen Xue, Yu Nie, Qi-Yong H Ai, Jiacheng Ma, Lulu Yang, Jihui Zhang, Sizhi Ai
    General Psychiatry.2023; 36(6): e101153.     CrossRef
  • Stress, Depression, and Unhealthy Behavior Changes among Patients with Diabetes during COVID-19 in Korea
    Hae Ran Kim, Jeong-Soon Kim
    Healthcare.2022; 10(2): 303.     CrossRef
  • Reply to comment on “Unexpected decline in glycated hemoglobin level after emergency COVID‐19 measures in three robust older Japanese women with prediabetes/mild type 2 diabetes”
    Tazuo Okuno, Osamu Iritani, Kumie Kodera, Daisuke Hama, Asami Kane, Kozue Morigaki, Toshio Terai, Norie Maeno, Shigeto Morimoto
    Geriatrics & Gerontology International.2022; 22(7): 541.     CrossRef
  • Anxiety, Distress and Stress among Patients with Diabetes during COVID-19 Pandemic: A Systematic Review and Meta-Analysis
    Rubén A. García-Lara, José L. Gómez-Urquiza, María José Membrive-Jiménez, Almudena Velando-Soriano, Monserrat E. Granados-Bolivar, José L. Romero-Béjar, Nora Suleiman-Martos
    Journal of Personalized Medicine.2022; 12(9): 1412.     CrossRef
  • Prevalence of Depression and Related Factors among Patients with Chronic Disease during the COVID-19 Pandemic: A Systematic Review and Meta-Analysis
    Rubén A. García-Lara, Nora Suleiman-Martos, María J. Membrive-Jiménez, Victoria García-Morales, Miguel Quesada-Caballero, Isabel M. Guisado-Requena, José L. Gómez-Urquiza
    Diagnostics.2022; 12(12): 3094.     CrossRef
COVID-19
Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study
Jae Hyun Bae, Sun Kyu Choi, Nam Hoon Kim, Juneyoung Lee, Sin Gon Kim
Diabetes Metab J. 2021;45(3):430-438.   Published online February 22, 2021
DOI: https://doi.org/10.4093/dmj.2020.0279
  • 7,660 View
  • 293 Download
  • 3 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Angiotensin-converting enzyme 2 facilitates the entry of severe acute respiratory syndrome coronavirus 2 into the human body. We investigated the association of renin-angiotensin-aldosterone system (RAAS) inhibitor use with severe coronavirus disease 2019 (COVID-19) outcomes in hypertensive patients.
Methods
We identified hypertensive patients with confirmed COVID-19 from the Korean Health Insurance Review and Assessment Service from inception to May 15, 2020. The primary outcome was the composite of intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), and death from COVID-19. The individual components were evaluated as secondary outcomes.
Results
Of 1,374 hypertensive patients with COVID-19, 1,076 (78.3%) and 298 (21.7%) were users and never-users of RAAS inhibitors, respectively. The RAAS inhibitor users were not associated with the risk of the primary outcome (adjusted odds ratio [aOR], 0.72; 95% confidence interval [CI], 0.46 to 1.10). The risk of ICU admission was significantly lower in the users than the never-users (aOR, 0.44; 95% CI, 0.24 to 0.84). The RAAS inhibitors were beneficial only in ICU admissions that did not require IMV (aOR, 0.28; 95% CI, 0.14 to 0.58). The risk of death from COVID-19 was comparable between the groups (aOR, 1.09; 95% CI, 0.64 to 1.85). We could not evaluate the risks of CRRT and ECMO owing to the small number of events.
Conclusion
RAAS inhibitor use was not associated with the composite of severe outcomes in the hypertensive patients with COVID-19 but significantly lowered the risk of ICU admission, particularly in patients who did not require IMV.

Citations

Citations to this article as recorded by  
  • Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19
    Nancy Xurui Huang, Qi Yuan, Fang Fang, Bryan P. Yan, John E. Sanderson, Masaki Mogi
    PLOS ONE.2023; 18(1): e0280280.     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
    Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
    Journal of the American Heart Association.2022;[Epub]     CrossRef
  • Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
    Rumen Filev, Lionel Rostaing, Mila Lyubomirova, Boris Bogov, Krassimir Kalinov, Dobrin Svinarov
    Medicine.2022; 101(48): e31988.     CrossRef
COVID-19
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
Diabetes Metab J. 2021;45(2):251-259.   Published online March 5, 2021
DOI: https://doi.org/10.4093/dmj.2020.0206
  • 7,638 View
  • 405 Download
  • 33 Web of Science
  • 34 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Dipeptidyl peptidase-4 inhibitor (DPP-4i) and renin-angiotensin system (RAS) blockade are reported to affect the clinical course of coronavirus disease 2019 (COVID-19) in patients with diabetes mellitus (DM).
Methods
As of May 2020, analysis was conducted on all subjects who could confirm their history of claims related to COVID-19 in the National Health Insurance Review and Assessment Service (HIRA) database in Korea. Using this dataset, we compared the short-term prognosis of COVID-19 infection according to the use of DPP-4i and RAS blockade. Additionally, we validated the results using the National Health Insurance Service (NHIS) of Korea dataset.
Results
Totally, data of 67,850 subjects were accessible in the HIRA dataset. Of these, 5,080 were confirmed COVID-19. Among these, 832 subjects with DM were selected for analysis in this study. Among the subjects, 263 (31.6%) and 327 (39.3%) were DPP4i and RAS blockade users, respectively. Thirty-four subjects (4.09%) received intensive care or died. The adjusted odds ratio for severe treatment among DPP-4i users was 0.362 (95% confidence interval [CI], 0.135 to 0.971), and that for RAS blockade users was 0.599 (95% CI, 0.251 to 1.431). These findings were consistent with the analysis based on the NHIS data using 704 final subjects. The adjusted odds ratio for severe treatment among DPP-4i users was 0.303 (95% CI, 0.135 to 0.682), and that for RAS blockade users was 0.811 (95% CI, 0.391 to 1.682).
Conclusion
This study suggests that DPP-4i is significantly associated with a better clinical outcome of patients with COVID-19.

Citations

Citations to this article as recorded by  
  • The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study
    Salvatore Greco, Vincenzo M. Monda, Giorgia Valpiani, Nicola Napoli, Carlo Crespini, Fabio Pieraccini, Anna Marra, Angelina Passaro
    Biomedicines.2023; 11(8): 2292.     CrossRef
  • Efficacy and Safety of Sitagliptin in the Treatment of COVID-19
    Ehab Mudher Mikhael, Siew Chin Ong, Siti Maisharah Sheikh Ghadzi
    Journal of Pharmacy Practice.2023; 36(4): 980.     CrossRef
  • DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
    Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Suprabhat Mukherjee, Rakesh Kundu
    Future Virology.2023; 18(5): 321.     CrossRef
  • Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
    Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
    Diabetologia.2023; 66(8): 1395.     CrossRef
  • ACE2, ACE, DPPIV, PREP and CAT L enzymatic activities in COVID-19: imbalance of ACE2/ACE ratio and potential RAAS dysregulation in severe cases
    Raquel Leão Neves, Jéssica Branquinho, Júlia Galanakis Arata, Clarissa Azevedo Bittencourt, Caio Perez Gomes, Michelle Riguetti, Gustavo Ferreira da Mata, Danilo Euclides Fernandes, Marcelo Yudi Icimoto, Gianna Mastroianni Kirsztajn, João Bosco Pesquero
    Inflammation Research.2023; 72(8): 1719.     CrossRef
  • Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
    Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
    Archives of Medical Research.2022; 53(2): 186.     CrossRef
  • Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
    Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
    Diabetes & Metabolism.2022; 48(1): 101307.     CrossRef
  • Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
    Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
    Primary Care Diabetes.2022; 16(1): 162.     CrossRef
  • Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
    Romil Singh, Sawai Singh Rathore, Hira Khan, Abhishek Bhurwal, Mack Sheraton, Prithwish Ghosh, Sohini Anand, Janaki Makadia, Fnu Ayesha, Kiran S. Mahapure, Ishita Mehra, Aysun Tekin, Rahul Kashyap, Vikas Bansal
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Short- and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes
    K Zhan, X Zhang, B Wang, Z Jiang, X Fang, S Yang, H Jia, L Li, G Cao, K Zhang, X Ma
    QJM: An International Journal of Medicine.2022; 115(3): 131.     CrossRef
  • Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients
    Ákos Nádasdi, György Sinkovits, Ilona Bobek, Botond Lakatos, Zsolt Förhécz, Zita Z Prohászka, Marienn Réti, Miklós Arató, Gellért Cseh, Tamás Masszi, Béla Merkely, Péter Ferdinandy, István Vályi-Nagy, Zoltán Prohászka, Gábor Firneisz
    Biomarkers in Medicine.2022; 16(5): 317.     CrossRef
  • Management von Diabetespatienten in der COVID-19-Pandemie
    Charlotte Steenblock, Carlotta Hoffmann, Tilman D. Rachner, Florian Guggenbichler, Ermal Tahirukaj, Sacipi Bejtullah, Vsevolod A. Zinserling, Zsuzanna Varga, Stefan R. Bornstein, Nikolaos Perakakis
    Diabetes aktuell.2022; 20(01): 43.     CrossRef
  • Letter: Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients (J Obes Metab Syndr 2021;30:149-54)
    Tae Jung Oh
    Journal of Obesity & Metabolic Syndrome.2022; 31(1): 86.     CrossRef
  • Glucose-Lowering Agents and COVID-19
    Ah Reum Khang
    The Journal of Korean Diabetes.2022; 23(1): 1.     CrossRef
  • The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
    Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients
    Verena Schöning, Felix Hammann
    Pharmaceutics.2022; 14(9): 1828.     CrossRef
  • Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
    Alba Sebastián-Martín, Belén G. Sánchez, José M. Mora-Rodríguez, Alicia Bort, Inés Díaz-Laviada
    Biomedicines.2022; 10(8): 2026.     CrossRef
  • Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19
    Aliah Alshanwani, Tarek Kashour, Amira Badr
    Endocrine, Metabolic & Immune Disorders - Drug Targets.2022; 22(6): 571.     CrossRef
  • Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
    Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
    World Journal of Virology.2022; 11(6): 399.     CrossRef
  • Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies
    Xiao-Ce Dai, Zhuo-Yu An, Zi-Yang Wang, Zi-Zhen Wang, Yi-Ren Wang
    Frontiers in Cardiovascular Medicine.2021;[Epub]     CrossRef
  • Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis
    Sabrina Schlesinger, Manuela Neuenschwander, Alexander Lang, Kalliopi Pafili, Oliver Kuss, Christian Herder, Michael Roden
    Diabetologia.2021; 64(7): 1480.     CrossRef
  • Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications
    Mariana Alves, Marília Andreia Fernandes, Gülistan Bahat, Athanase Benetos, Hugo Clemente, Tomasz Grodzicki, Manuel Martínez-Sellés, Francesco Mattace-Raso, Chakravarthi Rajkumar, Andrea Ungar, Nikos Werner, Timo E. Strandberg, Grodzicki, Strandberg
    European Geriatric Medicine.2021; 12(4): 725.     CrossRef
  • Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19
    Jose Manuel Ramos-Rincón, Luis M Pérez-Belmonte, Francisco Javier Carrasco-Sánchez, Sergio Jansen-Chaparro, Mercedes De-Sousa-Baena, José Bueno-Fonseca, Maria Pérez-Aguilar, Coral Arévalo-Cañas, Marta Bacete Cebrian, Manuel Méndez-Bailón, Isabel Fiteni Me
    The Journals of Gerontology: Series A.2021; 76(8): e102.     CrossRef
  • Managing diabetes in diabetic patients with COVID: where do we start from?
    Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
    Acta Diabetologica.2021; 58(11): 1441.     CrossRef
  • The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data
    João Malato, Franziska Sotzny, Sandra Bauer, Helma Freitag, André Fonseca, Anna D. Grabowska, Luís Graça, Clara Cordeiro, Luís Nacul, Eliana M. Lacerda, Jesus Castro-Marrero, Carmen Scheibenbogen, Francisco Westermeier, Nuno Sepúlveda
    Heliyon.2021; 7(8): e07665.     CrossRef
  • Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
    Sang Youl Rhee
    Diabetes & Metabolism Journal.2021; 45(4): 619.     CrossRef
  • Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
    Guntram Schernthaner
    Diabetes & Metabolism Journal.2021; 45(4): 615.     CrossRef
  • COVID-19 and metabolic disease: mechanisms and clinical management
    Charlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, Andreas Linkermann, Paul Zimmet, Konstantin Kulebyakin, Vsevolod A Tkachuk, Alexander G Markov, Hendrik Lehnert, Martin Hrabě de Angelis, Hannes Rietzsch, Roman N Rodionov, Kamlesh Khunti, David Hop
    The Lancet Diabetes & Endocrinology.2021; 9(11): 786.     CrossRef
  • Diabetes, Obesity, and COVID-19
    Sang Youl Rhee
    The Journal of Korean Diabetes.2021; 22(3): 174.     CrossRef
  • Sunlight Exposure and Phototherapy: Perspectives for Healthy Aging in an Era of COVID-19
    Toshiaki Nakano, Kuei-Chen Chiang, Chien-Chih Chen, Po-Jung Chen, Chia-Yun Lai, Li-Wen Hsu, Naoya Ohmori, Takeshi Goto, Chao-Long Chen, Shigeru Goto
    International Journal of Environmental Research and Public Health.2021; 18(20): 10950.     CrossRef
  • Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
    E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
    Kardiologiia.2021; 61(9): 20.     CrossRef
  • Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
    Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545.     CrossRef
  • COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
    Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
    Tianli Zhang, Xiang Tong, Shijie Zhang, Dongguang Wang, Lian Wang, Qian Wang, Hong Fan
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
Short Communication
COVID-19
Impact of Social Distancing Due to Coronavirus Disease 2019 on the Changes in Glycosylated Hemoglobin Level in People with Type 2 Diabetes Mellitus
Sung-Don Park, Sung-Woo Kim, Jun Sung Moon, Yin Young Lee, Nan Hee Cho, Ji-Hyun Lee, Jae-Han Jeon, Yeon-Kyung Choi, Mi Kyung Kim, Keun-Gyu Park
Diabetes Metab J. 2021;45(1):109-114.   Published online December 4, 2020
DOI: https://doi.org/10.4093/dmj.2020.0226
  • 9,202 View
  • 306 Download
  • 20 Web of Science
  • 21 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
This study investigated the impact of social distancing due to coronavirus disease 2019 (COVID-19) on glycemic control in people with type 2 diabetes mellitus (T2DM). We retrospectively analyzed the change in glycosylated hemoglobin level (ΔHbA1c) in people with T2DM who undertook social distancing because of COVID-19. We compared the ΔHbA1c between COVID-19 and non-COVID-19 cohorts that were enrolled at the same time of year. The ΔHbA1c of the COVID-19 cohort was significantly higher than that of two non-COVID-19 cohorts. Subgroup analysis according to age and baseline HbA1c level showed that social distancing significantly increased the mean HbA1c level of participants of <50 years. The ΔHbA1c of participants of <50 years and with HbA1c <7.0% in the COVID-19 cohort showed larger changes than other subgroups. In adjusted model, adjusted ΔHbA1c levels in the COVID-19 cohort remained significantly higher than those in the two other cohorts. Social distancing negatively impacts blood glucose control in people with T2DM, especially those who are younger and have good blood glucose control.

Citations

Citations to this article as recorded by  
  • Impact of two COVID-19 lockdowns on HbA1c levels in patients with type 2 diabetes and associations with patient characteristics: a multicentre, observational cohort study over three years
    Ingmar Schäfer, Daniel Tajdar, Laura Walther, Lasse Bittner, Dagmar Lühmann, Martin Scherer
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Self-Care of Adults with Type 2 Diabetes During the COVID-19 Pandemic: A Qualitative Interpretive Description Study
    Michela Luciani, Camilla Bigoni, Marta Canesi, Matteo Masotto, Diletta Fabrizi, Stefania Di Mauro, Davide Ausili
    Clinical Nursing Research.2023; 32(1): 73.     CrossRef
  • Changes in body weight and glycemic control in association with COVID-19 Shutdown among 23,000 adults with type 2 diabetes
    Emily Panza, Kevin E. Kip, Kripa Venkatakrishnan, Oscar C. Marroquin, Rena R. Wing
    Acta Diabetologica.2023; 60(6): 787.     CrossRef
  • The Impact of a Lockdown for the COVID-19 Pandemic on Seasonal HbA1c Variation in Patients with Type 2 Diabetes
    Yu-Cheng Cheng, Yu-Hsuan Li, Hsiu-Chen Liu, Chiann-Yi Hsu, Wan-Jen Chang, I-Te Lee, Chin-Li Lu
    Life.2023; 13(3): 763.     CrossRef
  • Changes in the mean incidence and variance of orthopedic diseases before and during the COVID-19 pandemic in Korea: a retrospective study
    Joo-Hee Kim, Mi Jung Kwon, Hyo Geun Choi, Sang Jun Lee, Sangwon Hwang, Jaemin Lee, San-Hui Lee, Jung Woo Lee
    BMC Musculoskeletal Disorders.2023;[Epub]     CrossRef
  • Gender differences-based bioinformatics analysis to identify hub genes and key pathways in type 2 diabetes
    Md Sojib Hossain, Subrina Islam Rupa, Md Sumon Sarkar, Md Al Amin, Mst Tania Khatun, Md Shamim, Md Zahidul Islam
    Informatics in Medicine Unlocked.2023; 40: 101302.     CrossRef
  • Retrospective Study on the Impact of COVID-19 Lockdown on Patients with Type 2 Diabetes in Northern Taiwan
    Hsuan Huang, Hsiao-Ling Su, Chih-Hsung Huang, Yi-Hsin Lin
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2539.     CrossRef
  • Understanding impacts of COVID-19 restrictions on glycemic control for patients with diabetes in Japan
    Kiyoko Uno-Eder, Noriko Satoh-Asahara, Manabu Hibiya, Kenji Uno, Takuya Uchino, Koji Morita, Toshio Ishikawa, Tetsuji Kaneko, Hajime Yamakage, Yuki Kitaoka, Tomohiro Sawa, Kazuhisa Tsukamoto, Tamio Teramoto
    Journal of Diabetes & Metabolic Disorders.2023; 22(2): 1695.     CrossRef
  • Impacts of the COVID-19 pandemic on unmet social needs, self-care, and outcomes among people with diabetes and poor glycemic control
    Minal R. Patel, Guanghao Zhang, Cindy Leung, Peter X.K. Song, Michele Heisler, Hae Mi Choe, Roshanak Mehdipanah, Xu Shi, Kenneth Resnicow, Geila Rajaee, John D. Piette
    Primary Care Diabetes.2022; 16(1): 57.     CrossRef
  • Impact of the COVID-19 Pandemic on Glycemic Control and Blood Pressure Control in Patients with Diabetes in Japan
    Keisuke Endo, Takayuki Miki, Takahito Itoh, Hirofumi Kubo, Ryosuke Ito, Kouhei Ohno, Hiroyuki Hotta, Nobuo Kato, Tomoaki Matsumoto, Aya Kitamura, Mai Tamayama, Takako Wataya, Ayaka Yamaya, Rei Ishikawa, Hitoshi Ooiwa
    Internal Medicine.2022; 61(1): 37.     CrossRef
  • The Effects of COVID-19 Lockdown on Glycaemic Control and Lipid Profile in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Omorogieva Ojo, Xiao-Hua Wang, Osarhumwese Osaretin Ojo, Edith Orjih, Nivedita Pavithran, Amanda Rodrigues Amorim Adegboye, Qian-Qian Feng, Paul McCrone
    International Journal of Environmental Research and Public Health.2022; 19(3): 1095.     CrossRef
  • Lifestyles Under Lockdown: A Scoping Review of International Studies on Type 2 Diabetes Self-Management Behaviors During COVID-19
    Caroline Cummings, Kagnica Seng, Ryan Tweet, Julie Wagner
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • Substitution of telemedicine for clinic visit during the COVID‐19 pandemic of 2020: Comparison of telemedicine and clinic visit
    Yukiko Onishi, Rieko Ichihashi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Toshiko Kobori, Tetsuya Kubota, Masahiko Iwamoto, Shoko Hamano, Masato Kasuga
    Journal of Diabetes Investigation.2022; 13(9): 1617.     CrossRef
  • The impact of the COVID-19 pandemic on the management of patients with chronic diseases in Primary Health Care
    Panagiotis Stachteas, Manolis Symvoulakis, Apostolos Tsapas, Emmanouil Smyrnakis
    Population Medicine.2022; 4(August): 1.     CrossRef
  • Effects of COVID-19 Pandemic and Lockdown on Monitoring and Treatment Balance of Finnish Coronary Heart Disease and Type 2 Diabetes Patients
    Piia Lavikainen, Marja-Leena Lamidi, Teppo Repo, Laura Inglin, Janne Martikainen, Tiina Laatikainen
    Clinical Epidemiology.2022; Volume 14: 1363.     CrossRef
  • Impact of Social Distancing Due to Coronavirus Disease 2019 on the Changes in Glycosylated Hemoglobin Level in People with Type 2 Diabetes Mellitus (Diabetes Metab J 2021;45:109-14)
    Junghyun Noh
    Diabetes & Metabolism Journal.2021; 45(2): 275.     CrossRef
  • Impact of Social Distancing Due to Coronavirus Disease 2019 on the Changes in Glycosylated Hemoglobin Level in People with Type 2 Diabetes Mellitus (Diabetes Metab J 2021;45:109-14)
    Sung-Don Park, Sung-Woo Kim, Jun Sung Moon, Jae-Han Jeon, Mi Kyung Kim, Keun-Gyu Park
    Diabetes & Metabolism Journal.2021; 45(2): 279.     CrossRef
  • Glucose control in diabetes during home confinement for the first pandemic wave of COVID-19: a meta-analysis of observational studies
    Giovanni Antonio Silverii, Chiara Delli Poggi, Ilaria Dicembrini, Matteo Monami, Edoardo Mannucci
    Acta Diabetologica.2021; 58(12): 1603.     CrossRef
  • The impact of COVID-19 pandemic on glycemic control in patients with diabetes mellitus in Turkey: a multi-center study from Kocaeli
    Alev Selek, Emre Gezer, Eda Altun, Mehmet Sözen, Ömercan Topaloğlu, Damla Köksalan, Halil Demirkan, Dilek Karakaya, Berrin Cetinarslan, Zeynep Cantürk, Dilek Taymez
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1461.     CrossRef
  • Effects of Social Distancing on Diabetes Management in Older Adults during COVID-19 Pandemic
    Soo Myoung Shin, Tae Jung Oh, Sung Hee Choi, Hak Chul Jang
    Diabetes & Metabolism Journal.2021; 45(5): 765.     CrossRef
  • Year-Long Trend in Glycated Hemoglobin Levels in Patients with Type 2 Diabetes during the COVID-19 Pandemic
    Jonghwa Jin, Seong Wook Lee, Won-Ki Lee, Jae-Han Jeon, Jung-Guk Kim, In-Kyu Lee, Yeon-Kyung Choi, Keun-Gyu Park
    Endocrinology and Metabolism.2021; 36(5): 1142.     CrossRef
Original Articles
COVID-19
Does Diabetes Increase the Risk of Contracting COVID-19? A Population-Based Study in Korea
Sung-Youn Chun, Dong Wook Kim, Sang Ah Lee, Su Jung Lee, Jung Hyun Chang, Yoon Jung Choi, Seong Woo Kim, Sun Ok Song
Diabetes Metab J. 2020;44(6):897-907.   Published online December 23, 2020
DOI: https://doi.org/10.4093/dmj.2020.0199
  • 7,333 View
  • 142 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
This study aimed to determine the infection risk of coronavirus disease 2019 (COVID-19) in patients with diabetes (according to treatment method).
Methods
Claimed subjects to the Korean National Health Insurance claims database diagnosed with COVID-19 were included. Ten thousand sixty-nine patients with COVID-19 between January 28 and April 5, 2020, were included. Stratified random sampling of 1:5 was used to select the control group of COVID-19 patients. In total 50,587 subjects were selected as the control group. After deleting the missing values, 60,656 subjects were included.
Results
Adjusted odds ratio (OR) indicated that diabetic insulin users had a higher risk of COVID-19 than subjects without diabetes (OR, 1.25; 95% confidence interval [CI], 1.03 to 1.53; P=0.0278). In the subgroup analysis, infection risk was higher among diabetes male insulin users (OR, 1.42; 95% CI, 1.07 to 1.89), those between 40 and 59 years (OR, 1.66; 95% CI, 1.13 to 2.44). The infection risk was higher in diabetic insulin users with 2 to 4 years of morbidity (OR, 1.744; 95% CI, 1.003 to 3.044).
Conclusion
Some diabetic patients with certain conditions would be associated with a higher risk of acquiring COVID-19, highlighting their need for special attention. Efforts are warranted to ensure that diabetic patients have minimal exposure to the virus. It is important to establish proactive care and screening tests for diabetic patients suspected with COVID-19 for timely disease diagnosis and management.

Citations

Citations to this article as recorded by  
  • Risk factors for SARS-CoV-2 infection during the early stages of the COVID-19 pandemic: a systematic literature review
    Matthew Harris, John Hart, Oashe Bhattacharya, Fiona M. Russell
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Diabetes mellitus, maternal adiposity, and insulin-dependent gestational diabetes are associated with COVID-19 in pregnancy: the INTERCOVID study
    Brenda Eskenazi, Stephen Rauch, Enrico Iurlaro, Robert B. Gunier, Albertina Rego, Michael G. Gravett, Paolo Ivo Cavoretto, Philippe Deruelle, Perla K. García-May, Mohak Mhatre, Mustapha Ado Usman, Mohamed Elbahnasawy, Saturday Etuk, Raffaele Napolitano, S
    American Journal of Obstetrics and Gynecology.2022; 227(1): 74.e1.     CrossRef
  • The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
    Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • COVID-19 and Gestational Diabetes: The Role of Nutrition and Pharmacological Intervention in Preventing Adverse Outcomes
    Ruben Ramirez Zegarra, Andrea Dall’Asta, Alberto Revelli, Tullio Ghi
    Nutrients.2022; 14(17): 3562.     CrossRef
  • A Comprehensive Analysis of Chinese, Japanese, Korean, US-PIMA Indian, and Trinidadian Screening Scores for Diabetes Risk Assessment and Prediction
    Norma Latif Fitriyani, Muhammad Syafrudin, Siti Maghfirotul Ulyah, Ganjar Alfian, Syifa Latif Qolbiyani, Muhammad Anshari
    Mathematics.2022; 10(21): 4027.     CrossRef
  • The World-Wide Adaptations of Diabetic Management in the Face of COVID-19 and Socioeconomic Disparities: A Scoping Review
    Jaafar Abou-Ghaida, Annalia Foster, Sarah Klein, Massah Bassie, Khloe Gu, Chloe Hille, Cody Brown, Michael Daniel, Caitlin Drakeley, Alek Jahnke, Abrar Karim, Omar Altabbakh, Luzan Phillpotts
    Cureus.2022;[Epub]     CrossRef
  • Dissection of non-pharmaceutical interventions implemented by Iran, South Korea, and Turkey in the fight against COVID-19 pandemic
    Mohammad Keykhaei, Sogol Koolaji, Esmaeil Mohammadi, Reyhaneh Kalantar, Sahar Saeedi Moghaddam, Arya Aminorroaya, Shaghayegh Zokaei, Sina Azadnajafabad, Negar Rezaei, Erfan Ghasemi, Nazila Rezaei, Rosa Haghshenas, Yosef Farzi, Sina Rashedi, Bagher Larijan
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1919.     CrossRef
COVID-19
Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study
Sun Joon Moon, Eun-Jung Rhee, Jin-Hyung Jung, Kyung-Do Han, Sung-Rae Kim, Won-Young Lee, Kun-Ho Yoon
Diabetes Metab J. 2020;44(5):737-746.   Published online October 21, 2020
DOI: https://doi.org/10.4093/dmj.2020.0141
  • 10,317 View
  • 201 Download
  • 20 Web of Science
  • 23 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Inconsistent results have been observed regarding the independent effect of diabetes on the severity of coronavirus disease 2019 (COVID-19). We conducted a nationwide population-based cohort study to evaluate the relationship between diabetes and COVID-19 severity in South Korea.
Methods
Patients with laboratory-confirmed COVID-19 aged ≥30 years were enrolled and medical claims data were obtained from the Korean Health Insurance Review and Assessment Service. Hospitalization, oxygen treatment, ventilator application, and mortality were assessed as severity outcomes. Multivariate logistic regression analyses were performed after adjusting for age, sex, and comorbidities.
Results
Of 5,307 COVID-19 patients, the mean age was 56.0±14.4 years, 2,043 (38.5%) were male, and 770 (14.5%) had diabetes. The number of patients who were hospitalized, who received oxygen, who required ventilator support, and who died was 4,986 (94.0%), 884 (16.7%), 121 (2.3%), and 211 (4.0%), respectively. The proportion of patients with diabetes in the abovementioned outcome groups was 14.7%, 28.1%, 41.3%, 44.6%, showing an increasing trend according to outcome severity. In multivariate analyses, diabetes was associated with worse outcomes, with an adjusted odds ratio (aOR) of 1.349 (95% confidence interval [CI], 1.099 to 1.656; P=0.004) for oxygen treatment, an aOR of 1.930 (95% CI, 1.276 to 2.915; P<0.001) for ventilator use, and an aOR of 2.659 (95% CI, 1.896 to 3.729; P<0.001) for mortality.
Conclusion
Diabetes was associated with worse clinical outcomes in Korean patients with COVID-19, independent of other comorbidities. Therefore, patients with diabetes and COVID-19 should be treated with caution.

Citations

Citations to this article as recorded by  
  • Impact of COVID-19 on the Microbiome and Inflammatory Status of Type 2 Diabetes Patients
    Gratiela Gradisteanu Pircalabioru, Georgiana Alexandra Grigore, Ilda Czobor Barbu, Mariana-Carmen Chifiriuc, Octavian Savu
    Biomedicines.2023; 11(1): 179.     CrossRef
  • Bidirectional Relationship between Glycemic Control and COVID-19 and Perspectives of Islet Organoid Models of SARS-CoV-2 Infection
    Tongran Zhang, Nannan Wang, Lingqiang Zhu, Lihua Chen, Huisheng Liu
    Biomedicines.2023; 11(3): 856.     CrossRef
  • Reasons for Hospitalization Among Australians With Type 1 or Type 2 Diabetes and COVID-19
    Dunya Tomic, Jonathan E. Shaw, Dianna J. Magliano
    Canadian Journal of Diabetes.2023;[Epub]     CrossRef
  • Anti-SARS-CoV-2 antibody levels predict outcome in COVID-19 patients with type 2 diabetes: a prospective cohort study
    Sylvia Mink, Christoph H. Saely, Andreas Leiherer, Matthias Frick, Thomas Plattner, Heinz Drexel, Peter Fraunberger
    Scientific Reports.2023;[Epub]     CrossRef
  • Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium
    Thomas Servais, France Laurent, Thomas Roland, Camelia Rossi, Elodie De Groote, Valérie Godart, Ernestina Repetto, Michel Ponchon, Pascale Chasseur, Laurent Crenier, Sandrine Van Eeckhoudt, John Yango, Philippe Oriot, Mirela Morisca Gavriliu, Stéphanie Ro
    Annales d'Endocrinologie.2023;[Epub]     CrossRef
  • Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations
    Dan Ziegler, Solomon Tesfaye, Vincenza Spallone, Irina Gurieva, Juma Al Kaabi, Boris Mankovsky, Emil Martinka, Gabriela Radulian, Khue Thy Nguyen, Alin O Stirban, Tsvetalina Tankova, Tamás Varkonyi, Roy Freeman, Péter Kempler, Andrew JM Boulton
    Diabetes Research and Clinical Practice.2022; 186: 109063.     CrossRef
  • The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
    Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • The interrelationship between diabetes mellitus and COVID-19
    ThekraAbdulaali Abed, ZainabAdil Ghani Chabuck
    Medical Journal of Babylon.2022; 19(1): 1.     CrossRef
  • Impact of Type 2 Diabetes Mellitus on the Incidence and Outcomes of COVID-19 Needing Hospital Admission According to Sex: Retrospective Cohort Study Using Hospital Discharge Data in Spain, Year 2020
    Jose M. de Miguel-Yanes, Rodrigo Jimenez-Garcia, Javier de Miguel-Diez, Valentin Hernández-Barrera, David Carabantes-Alarcon, Jose J. Zamorano-Leon, Ricardo Omaña-Palanco, Ana Lopez-de-Andres
    Journal of Clinical Medicine.2022; 11(9): 2654.     CrossRef
  • Diabetes Fact Sheet in Korea 2021
    Jae Hyun Bae, Kyung-Do Han, Seung-Hyun Ko, Ye Seul Yang, Jong Han Choi, Kyung Mook Choi, Hyuk-Sang Kwon, Kyu Chang Won
    Diabetes & Metabolism Journal.2022; 46(3): 417.     CrossRef
  • The burden and risks of emerging complications of diabetes mellitus
    Dunya Tomic, Jonathan E. Shaw, Dianna J. Magliano
    Nature Reviews Endocrinology.2022; 18(9): 525.     CrossRef
  • Clinical Characteristics and Outcomes of Patients Hospitalized with COVID-19 at Case Hospital, Uganda
    Mirriam Apiyo, Ronald Olum, Amina Kabuye, Betty Khainza, Anne M. Amate, Vittal Byabashaija, Derrick Nomujuni, Kato Sebbaale, Peter Senfuka, Simon Kazibwe, Gurav Sharma, Lindsay Davidson, Felix Bongomin, Diamantis Kofteridis
    Interdisciplinary Perspectives on Infectious Diseases.2022; 2022: 1.     CrossRef
  • Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
    Daniel J. Drucker
    Cell Metabolism.2021; 33(3): 479.     CrossRef
  • Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
    Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
    Diabetes & Metabolism Journal.2021; 45(2): 251.     CrossRef
  • COVID-19 vaccine acceptance among high-risk populations in Uganda
    Felix Bongomin, Ronald Olum, Irene Andia-Biraro, Frederick Nelson Nakwagala, Khalid Hudow Hassan, Dianah Rhoda Nassozi, Mark Kaddumukasa, Pauline Byakika-Kibwika, Sarah Kiguli, Bruce J. Kirenga
    Therapeutic Advances in Infectious Disease.2021; 8: 204993612110243.     CrossRef
  • Caracterización clínica, según niveles de glucemia, de pacientes hospitalizados por COVID-19: serie de casos
    Irene Stulin, Maria Montes de Oca, Gabriela Blanco, Laura Sánchez, Isabel-Carlota Silva, Jennireth Quevedo, Maria Cristina Arvelo, Nathalia Valera, Irene Papa, Hospital Centro Médico de Caracas, Caracas, Venezuela Bacci, Fátima de Abreu, Héctor Villarroel
    Investigación Clínica.2021; 62: 27.     CrossRef
  • COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
    Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
  • Diabetes Mellitus and COVID-19: Review Article
    Mahmoud Nassar, Ahmed Daoud, Nso Nso, Luis Medina, Victoria Ghernautan, Harangad Bhangoo, Andrew Nyein, Mahmoud Mohamed, Ahmed Alqassieh, Karim Soliman, Mostafa Alfishawy, Issac Sachmechi, Anoop Misra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(6): 102268.     CrossRef
  • Dissection of non-pharmaceutical interventions implemented by Iran, South Korea, and Turkey in the fight against COVID-19 pandemic
    Mohammad Keykhaei, Sogol Koolaji, Esmaeil Mohammadi, Reyhaneh Kalantar, Sahar Saeedi Moghaddam, Arya Aminorroaya, Shaghayegh Zokaei, Sina Azadnajafabad, Negar Rezaei, Erfan Ghasemi, Nazila Rezaei, Rosa Haghshenas, Yosef Farzi, Sina Rashedi, Bagher Larijan
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1919.     CrossRef
  • A Systematic Review and Meta-analysis of Diabetes Associated Mortality in Patients with COVID-19
    Puneeta Gupta, Meeta Gupta, Neena KAtoch, Ketan Garg, Bhawna Garg
    International Journal of Endocrinology and Metabolism.2021;[Epub]     CrossRef
  • Diabetes, Obesity, and COVID-19
    Sang Youl Rhee
    The Journal of Korean Diabetes.2021; 22(3): 174.     CrossRef
  • Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies
    Yahya Mahamat-Saleh, Thibault Fiolet, Mathieu Edouard Rebeaud, Matthieu Mulot, Anthony Guihur, Douae El Fatouhi, Nasser Laouali, Nathan Peiffer-Smadja, Dagfinn Aune, Gianluca Severi
    BMJ Open.2021; 11(10): e052777.     CrossRef
  • Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide-Cohort Study (Diabetes Metab J 2020;44:737-46)
    Kyuho Kim, Tae Jung Oh
    Diabetes & Metabolism Journal.2020; 44(6): 938.     CrossRef
Covid-19
The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea
Mi Kyung Kim, Jae-Han Jeon, Sung-Woo Kim, Jun Sung Moon, Nan Hee Cho, Eugene Han, Ji Hong You, Ji Yeon Lee, Miri Hyun, Jae Seok Park, Yong Shik Kwon, Yeon-Kyung Choi, Ki Tae Kwon, Shin Yup Lee, Eon Ju Jeon, Jin-Woo Kim, Hyo-Lim Hong, Hyun Hee Kwon, Chi Young Jung, Yin Young Lee, Eunyeoung Ha, Seung Min Chung, Jian Hur, June Hong Ahn, Na-young Kim, Shin-Woo Kim, Hyun Ha Chang, Yong Hoon Lee, Jaehee Lee, Keun-Gyu Park, Hyun Ah Kim, Ji-Hyun Lee
Diabetes Metab J. 2020;44(4):602-613.   Published online August 12, 2020
DOI: https://doi.org/10.4093/dmj.2020.0146
  • 12,941 View
  • 204 Download
  • 64 Web of Science
  • 72 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than eight million people worldwide by June 2020. Given the importance of the presence of diabetes mellitus (DM) for host immunity, we retrospectively evaluated the clinical characteristics and outcomes of moderate-to-severe COVID-19 in patients with diabetes.

Methods

We conducted a multi-center observational study of 1,082 adult inpatients (aged ≥18 years) who were admitted to one of five university hospitals in Daegu because of the severity of their COVID-19-related disease. The demographic, laboratory, and radiologic findings, and the mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM. In addition, 1:1 propensity score (PS)-matching was conducted with the DM group.

Results

Compared with the non-DM group (n=847), patients with DM (n=235) were older, exhibited higher mortality, and required more intensive care. Even after PS-matching, patients with DM exhibited more severe disease, and DM remained a prognostic factor for higher mortality (hazard ratio, 2.40; 95% confidence interval, 1.38 to 4.15). Subgroup analysis revealed that the presence of DM was associated with higher mortality, especially in older people (≥70 years old). Prior use of a dipeptidyl peptidase-4 inhibitor or a renin-angiotensin system inhibitor did not affect mortality or the clinical severity of the disease.

Conclusion

DM is a significant risk factor for COVID-19 severity and mortality. Our findings imply that COVID-19 patients with DM, especially if elderly, require special attention and prompt intensive care.

Citations

Citations to this article as recorded by  
  • Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
    Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
    Diabetes Research and Clinical Practice.2023; 195: 110205.     CrossRef
  • Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
    Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
    Diabetologia.2023; 66(8): 1395.     CrossRef
  • Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
    A. V. Alieva, A. A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Z. Khalilova, V. A. Talenova, N. U. Alimova, M. D. Aripova, A. S. Sadikova
    Obesity and metabolism.2023; 20(2): 92.     CrossRef
  • Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
    Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
    Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
  • Epidemiological features and consequences of COVID‐19 in patients with and without gastrointestinal symptoms in southwestern Iran. A retrospective observational study
    Habibollah Azarbakhsh, Leila Moftakhar, Aliasghar Valipour, Alireza Mirahmadizadeh, Hekmat Allah Moradi, Elahe Piraee
    Health Science Reports.2023;[Epub]     CrossRef
  • The Impact of Long-Term Conditions and Comorbidity Patterns on COVID-19 Infection and Hospitalisation: A Cohort Study
    Yun-Ting Huang, Andrew Steptoe, Riyaz S. Patel, Esme Fuller Thomson, Dorina Cadar
    Gerontology.2023; 69(10): 1200.     CrossRef
  • Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
    Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
    Archives of Medical Research.2022; 53(2): 186.     CrossRef
  • Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
    Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
    Diabetes & Metabolism.2022; 48(1): 101307.     CrossRef
  • Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
    Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
    Primary Care Diabetes.2022; 16(1): 162.     CrossRef
  • Prevalence and impact of diabetes in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
    Sian A. Bradley, Maciej Banach, Negman Alvarado, Ivica Smokovski, Sonu M. M. Bhaskar
    Journal of Diabetes.2022; 14(2): 144.     CrossRef
  • Interplay between Inflammaging, Frailty and Nutrition in Covid-19: Preventive and Adjuvant Treatment Perspectives
    A. Padilha de Lima, M. Macedo Rogero, T. Araujo Viel, H.M. Garay-Malpartida, I. Aprahamian, Sandra Maria Lima Ribeiro
    The Journal of nutrition, health and aging.2022; 26(1): 67.     CrossRef
  • Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study
    Mi Seon Lee, Rosie Lee, Cheol Woo Ko, Jung Eun Moon
    Journal of Yeungnam Medical Science.2022; 39(1): 46.     CrossRef
  • Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network
    Qian Gao, Wenjun Zhang, Tingting Li, Guojun Yang, Wei Zhu, Naijun Chen, Huawei Jin
    Scientific Reports.2022;[Epub]     CrossRef
  • Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation
    Afnan Alshnbari, Iskandar Idris
    Current Medical Research and Opinion.2022; 38(3): 357.     CrossRef
  • Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
    Li-Min Zhao, Xie-Hui Chen, Mei Qiu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • COVID-19 and Diabetes
    Awadhesh Kumar Singh, Kamlesh Khunti
    Annual Review of Medicine.2022; 73(1): 129.     CrossRef
  • The enzymes in COVID-19: A review
    Maria Helena Menezes Estevam Alves, Layla Carvalho Mahnke, Tifany Cerqueira Macedo, Thais Ketinly dos Santos Silva, Luiz Bezerra Carvalho Junior
    Biochimie.2022; 197: 38.     CrossRef
  • IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW
    Adnan A. Zainal, Marwan M. Merkhan
    Military Medical Science Letters.2022; 91(2): 140.     CrossRef
  • Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis
    Adithan Ganesh, Michael D. Randall
    British Journal of Clinical Pharmacology.2022; 88(6): 2642.     CrossRef
  • Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin
    Clifford J. Bailey, Mike Gwilt
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
    Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
    Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
    Metabolism.2022; 131: 155196.     CrossRef
  • Glucose-Lowering Agents and COVID-19
    Ah Reum Khang
    The Journal of Korean Diabetes.2022; 23(1): 1.     CrossRef
  • Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis
    Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
    Endocrinology, Diabetes & Metabolism.2022;[Epub]     CrossRef
  • The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
    Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
    Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
    Journal of the American Heart Association.2022;[Epub]     CrossRef
  • Diabetes and SARS-CoV-2–Is There a Mutual Connection?
    Anna P. Jedrzejak, Edyta K. Urbaniak, Jadwiga A. Wasko, Natalia Ziojla, Malgorzata Borowiak
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2022; 11: 729.     CrossRef
  • Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?
    Marzieh Rohani-Rasaf, Kosar Mirjalili, Akram Vatannejad, Maryam Teimouri, Xiao-Feng Yang
    PLOS ONE.2022; 17(8): e0272000.     CrossRef
  • Early glycaemic variability increases 28-day mortality and prolongs intensive care unit stay in critically ill patients with pneumonia
    Seong Ho Kim, Ji Young Kim, Eun Song Kim, Il Rae Park, Eun Yeong Ha, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
    Annals of Medicine.2022; 54(1): 2724.     CrossRef
  • Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
    Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
    World Journal of Virology.2022; 11(6): 399.     CrossRef
  • Prevalencia de secuelas en pacientes con diabetes mellitus tipo 2 sobrevivientes al COVID-19
    Gianela M. Cancino-Castillo, Miguel A. Tresierra-Ayala, Jorge L. Campos-Reyna, Jaime Rosales-Rimache
    REVISTA MÉDICA VALLEJIANA/ Vallejian Medical Journal.2022; 11(2): 48.     CrossRef
  • Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq
    Hussein Nafakhi, Mohammed Alareedh, Karrar Al-Buthabhak, Foaad Shaghee, Ahmed Nafakhi, Samet Kasim
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 33.     CrossRef
  • Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
    Awadhesh Kumar Singh, Ritu Singh, Banshi Saboo, Anoop Misra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 159.     CrossRef
  • COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis
    Mark Thomaz Ugliara Barone, Belinda Ngongo, Simone Bega Harnik, Lucas Xavier de Oliveira, Dániel Végh, Patrícia Vieira de Luca, Hermelinda Cordeiro Pedrosa, Franco Giraudo, Roque Cardona-Hernandez, Nayanjeet Chaudhury, Luiz Menna-Barreto
    Diabetes Research and Clinical Practice.2021; 171: 108587.     CrossRef
  • A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
    Chia Siang Kow, Syed Shahzad Hasan
    Therapies.2021; 76(4): 361.     CrossRef
  • Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
    B. M. Bonora, A. Avogaro, G. P. Fadini
    Journal of Endocrinological Investigation.2021; 44(7): 1379.     CrossRef
  • Prognostic bioindicators in severe COVID-19 patients
    L. Bergantini, E. Bargagli, M. d'Alessandro, R.M. Refini, P. Cameli, L. Galasso, C. Scapellato, F. Montagnani, S. Scolletta, F. Franchi, S. Valente, D. Bennett, G. Sebastiani, B. Frediani, F. Dotta
    Cytokine.2021; 141: 155455.     CrossRef
  • Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients
    Leila Moftakhar, Parisa Moftakhar, Elahe Piraee, Haleh Ghaem, Aliasghar Valipour, Habibollah Azarbakhsh
    International Journal of Diabetes in Developing Countries.2021; 41(3): 383.     CrossRef
  • DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
    André J. Scheen
    Diabetes & Metabolism.2021; 47(2): 101213.     CrossRef
  • Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
    Ronan Roussel, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, Leila Ait Bachir, Ingrid Allix, Deborah Ancelle, Sara Barraud, Lyse Bordier, Aurélie Carlier, Nicolas Chevalier, Christine Coffin‐Boutreux, Emmanuel Cosson, Anne Dorange, O
    Diabetes, Obesity and Metabolism.2021; 23(5): 1162.     CrossRef
  • Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis
    Rimesh Pal, Mainak Banerjee, Soham Mukherjee, Ranjitpal Singh Bhogal, Amanpreet Kaur, Sanjay K. Bhadada
    Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882199648.     CrossRef
  • Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
    Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, Giovanni Corrao, Franz H. Messerli
    Journal of Hypertension.2021; 39(4): 784.     CrossRef
  • Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis
    Zeinab Abdelrahman, Qian Liu, Shanmei Jiang, Mengyuan Li, Qingrong Sun, Yue Zhang, Xiaosheng Wang
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
    Timotius Ivan Hariyanto, Andree Kurniawan
    Journal of Diabetes & Metabolic Disorders.2021; 20(1): 543.     CrossRef
  • Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis
    Halla Kaminska, Lukasz Szarpak, Dariusz Kosior, Wojciech Wieczorek, Agnieszka Szarpak, Mahdi Al-Jeabory, Wladyslaw Gawel, Aleksandra Gasecka, Milosz J. Jaguszewski, Przemyslawa Jarosz-Chobot
    Acta Diabetologica.2021; 58(8): 1101.     CrossRef
  • Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression
    Iis Inayati Rakhmat, Yudith Yunia Kusmala, Dewi Ratih Handayani, Henny Juliastuti, Eka Noneng Nawangsih, Arief Wibowo, Michael Anthonius Lim, Raymond Pranata
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(3): 777.     CrossRef
  • Post-infection depressive, anxiety and post-traumatic stress symptoms: A prospective cohort study in patients with mild COVID-19
    Flavia Ismael, João C.S. Bizario, Tatiane Battagin, Beatriz Zaramella, Fabio E. Leal, Julio Torales, Antonio Ventriglio, Megan E. Marziali, Silvia S. Martins, João M. Castaldelli-Maia
    Progress in Neuro-Psychopharmacology and Biological Psychiatry.2021; 111: 110341.     CrossRef
  • Managing diabetes in diabetic patients with COVID: where do we start from?
    Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
    Acta Diabetologica.2021; 58(11): 1441.     CrossRef
  • Is diabetes mellitus a wrongdoer to COVID-19 severity?
    Sanjib Sarkar, Dibyendu Das, Sawlang Borsingh Wann, Jatin Kalita, Prasenjit Manna
    Diabetes Research and Clinical Practice.2021; 178: 108936.     CrossRef
  • Dipeptidyl Peptidase 4 Inhibitor, an Update
    Ju Hee Lee
    The Journal of Korean Diabetes.2021; 22(2): 91.     CrossRef
  • Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19
    Zhenmu Jin, Mo Zheng, Jichan Shi, Xinchun Ye, Fang Cheng, Que-Lu Chen, Jianping Huang, Xian-Gao Jiang
    Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
  • Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
    Anna R. Kahkoska, Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Stürmer, Kajsa Kvist, John B. Buse, Tim Q. Duong
    Diabetes Care.2021; 44(7): 1564.     CrossRef
  • The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus
    Wenxing Yang, Xuehong Sun, Jun Zhang, Kui Zhang
    Diabetes Research and Clinical Practice.2021; 178: 108977.     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
    Jordan Loader, Erik Lampa, Stefan Gustafsson, Thomas Cars, Johan Sundström
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus
    Ayça Elibol, Didem Eren, Macide Deniz Erdoğan, Merve Elmaağaç, Oguzhan Sıtkı Dizdar, İlhami Çelik, Ali İhsan Günal
    Primary Care Diabetes.2021; 15(5): 806.     CrossRef
  • Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors
    Melina Farshbafnadi, Sara Kamali Zonouzi, Mohammadmahdi Sabahi, Mahsa Dolatshahi, Mohammad Hadi Aarabi
    Experimental Gerontology.2021; 154: 111507.     CrossRef
  • Classical and Counter-Regulatory Renin–Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology
    Moudhi Almutlaq, Abir Abdullah Alamro, Fayhan Alroqi, Tlili Barhoumi
    CJC Open.2021; 3(8): 1060.     CrossRef
  • Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
    Yin Li, Xue Yang, Peijing Yan, Tong Sun, Zhi Zeng, Sheyu Li
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
    Marina Treskova-Schwarzbach, Laura Haas, Sarah Reda, Antonia Pilic, Anna Borodova, Kasra Karimi, Judith Koch, Teresa Nygren, Stefan Scholz, Viktoria Schönfeld, Sabine Vygen-Bonnet, Ole Wichmann, Thomas Harder
    BMC Medicine.2021;[Epub]     CrossRef
  • COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
    Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
  • High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
    Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 800.     CrossRef
  • Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
    Chengxia Kan, Yang Zhang, Fang Han, Qian Xu, Tongtong Ye, Ningning Hou, Xiaodong Sun
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
    E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
    Kardiologiia.2021; 61(9): 20.     CrossRef
  • Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
    Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545.     CrossRef
  • COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
    Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis
    Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Decision Trees: Predictions of Global Vulnerability to Coronavirus Outbreaks
    Moacir José da Silva
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis
    Liman Luo, Menglu Fu, Yuanyuan Li, Shuiqing Hu, Jinlan Luo, Zhihui Chen, Jing Yu, Wenhua Li, Ruolan Dong, Yan Yang, Ling Tu, Xizhen Xu
    Clinical Cardiology.2020; 43(12): 1478.     CrossRef
  • The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
    Antonia Anna Lukito, Raymond Pranata, Joshua Henrina, Michael Anthonius Lim, Sherly Lawrensia, Ketut Suastika
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2177.     CrossRef
  • Risk Factors on the Progression to Clinical Outcomes of COVID-19 Patients in South Korea: Using National Data
    Seon-Rye Kim, Seoul-Hee Nam, Yu-Rin Kim
    International Journal of Environmental Research and Public Health.2020; 17(23): 8847.     CrossRef
  • Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea
    Ji Hong You, Sang Ah Lee, Sung-Youn Chun, Sun Ok Song, Byung-Wan Lee, Dae Jung Kim, Edward J. Boyko
    Endocrinology and Metabolism.2020; 35(4): 901.     CrossRef
Review
Complications
Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective
Junghyun Noh, Hyun-Ha Chang, In-Kyung Jeong, Kun Ho Yoon
Diabetes Metab J. 2020;44(3):372-381.   Published online June 29, 2020
DOI: https://doi.org/10.4093/dmj.2020.0138
  • 7,988 View
  • 138 Download
  • 11 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   

Diabetes has been associated with more severe outcomes and higher mortality in coronavirus disease 2019 (COVID-19) patients compare to morbidity and mortality in patients without diabetes. Several mechanisms may play a role in this greater morbidity and mortality, especially uncontrolled hyperglycemia, an impaired immune system, pre-existing proinflammatory states, multiple comorbidities, and dysregulated angiotensin-converting enzyme 2 signaling. Thus, the diabetes medical community emergently needs to know about COVID-19 and its effects on patients with diabetes, as they must take precautions to carefully manage these patients during the COVID-19 pandemic. The Korean Diabetes Association provides some guidance and practical recommendations for the management of diabetes during the pandemic. This report provides insight into the association between diabetes and COVID-19, proper management of diabetes in patients with COVID-19 and an official suggestion by the Korean Diabetes Association for managing the COVID-19 outbreak.

Citations

Citations to this article as recorded by  
  • Medical comorbidities as predictors of COVID-19 short-term mortality: A historical cohort study in Indonesia
    RizaldyTaslim Pinzon, Vanessa Veronica
    Tzu Chi Medical Journal.2023; 35(1): 53.     CrossRef
  • A year of experience with COVID‐19 in patients with cancer: A nationwide study
    Mina Khosravifar, Sogol Koolaji, Negar Rezaei, Ali Ghanbari, Seyedeh Melika Hashemi, Erfan Ghasemi, Ali Bitaraf, Ozra Tabatabaei‐Malazy, Nazila Rezaei, Sahar Mohammadi Fateh, Arezou Dilmaghani‐Marand, Rosa Haghshenas, Ameneh Kazemi, Erfan Pakatchian, Farz
    Cancer Reports.2023;[Epub]     CrossRef
  • Impact of COPD on clinical and CT characteristics of COVID-19-associated pneumonia: single tertiary center experience
    Yevgeniya Filippenko, Marianna Zagurovskaya, Aigul Abdrakhmanova, Saule Kassenova, Zhanar Zhakenova, Aizat Aimakhanova, Zhamilya Zholdybay
    Egyptian Journal of Radiology and Nuclear Medicine.2022;[Epub]     CrossRef
  • Being caught in the perfect storm of a diabetes epidemic and the COVID‐19 pandemic: What should we do for our patients?
    Yunjung Cho, Kun‐Ho Yoon
    Journal of Diabetes Investigation.2021; 12(3): 297.     CrossRef
  • COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis
    Mark Thomaz Ugliara Barone, Belinda Ngongo, Simone Bega Harnik, Lucas Xavier de Oliveira, Dániel Végh, Patrícia Vieira de Luca, Hermelinda Cordeiro Pedrosa, Franco Giraudo, Roque Cardona-Hernandez, Nayanjeet Chaudhury, Luiz Menna-Barreto
    Diabetes Research and Clinical Practice.2021; 171: 108587.     CrossRef
  • Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea
    Sang Chul Lee, Kang Ju Son, Chang Hoon Han, Seon Cheol Park, Ji Ye Jung
    Scientific Reports.2021;[Epub]     CrossRef
  • Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
    Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
    Diabetes & Metabolism Journal.2021; 45(2): 251.     CrossRef
  • Towards Telemedicine Adoption in Korea: 10 Practical Recommendations for Physicians
    Hun-Sung Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Nutritional information access and dietary behavior among people with diabetes during Covid-19 pandemic
    Yovita Puri Subardjo, Gumintang Ratna Ramadhan, Dika Betaditya, Muflihatus Syarifah, Nurafifah Fauziana Abidin
    IOP Conference Series: Earth and Environmental Science.2021; 746(1): 012027.     CrossRef
  • Dissection of non-pharmaceutical interventions implemented by Iran, South Korea, and Turkey in the fight against COVID-19 pandemic
    Mohammad Keykhaei, Sogol Koolaji, Esmaeil Mohammadi, Reyhaneh Kalantar, Sahar Saeedi Moghaddam, Arya Aminorroaya, Shaghayegh Zokaei, Sina Azadnajafabad, Negar Rezaei, Erfan Ghasemi, Nazila Rezaei, Rosa Haghshenas, Yosef Farzi, Sina Rashedi, Bagher Larijan
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1919.     CrossRef
  • 2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
    Seung-Hyun Ko
    The Journal of Korean Diabetes.2021; 22(4): 244.     CrossRef
  • Clinical Characteristics and Mortality Predictors of COVID-19 Patients Hospitalized at Nationally-Designated Treatment Hospitals
    Seong-Su Moon, Kwan Lee, Jungi Park, Seongcheol Yun, Yun Sik Lee, Dong Seok Lee
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Response: The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study (Diabetes Metab J 2020;44:405–13)
    Seung Min Chung, June Hong Ahn, Jun Sung Moon
    Diabetes & Metabolism Journal.2020; 44(4): 625.     CrossRef
  • Diabetes Mellitus and COVID-19
    Jeong Hyun Park
    The Journal of Korean Diabetes.2020; 21(3): 116.     CrossRef
Original Article
Complications
The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study
Seung Min Chung, Yin Young Lee, Eunyeong Ha, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Jian Hur, Kyung Soo Hong, Jong Geol Jang, Hyun Jung Jin, Eun Young Choi, Kyeong-Cheol Shin, Jin Hong Chung, Kwan Ho Lee, June Hong Ahn, Jun Sung Moon
Diabetes Metab J. 2020;44(3):405-413.   Published online May 21, 2020
DOI: https://doi.org/10.4093/dmj.2020.0105
  • 9,883 View
  • 143 Download
  • 43 Web of Science
  • 45 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

To determine the role of diabetes mellitus (DM) in the coronavirus disease 2019 (COVID-19), we explored the clinical characteristics of patients with DM and compared risk factors such as age, glycemic control, and medications to those without DM.

Methods

This was a retrospective cohort study of 117 confirmed patients with COVID-19 which conducted at a tertiary hospital in Daegu, South Korea. The primary outcome was defined as the severe and critical outcome (SCO), of which the composite outcomes of acute respiratory distress syndrome, septic shock, intensive care unit care, and 28-day mortality. We analyzed what clinical features and glycemic control-related factors affect the prognosis of COVID-19 in the DM group.

Results

After exclusion, 110 participants were finally included. DM patients (n=29) was older, and showed higher blood pressure compared to non-DM patients. DM group showed higher levels of inflammation-related biomarkers and severity score, and highly progressed to SCO. After adjustment with other risk factors, DM increased the risk of SCO (odds ratio [OR], 10.771; P<0.001). Among the DM patients, SCO was more prevalent in elderly patients of ≥70 years old and age was an independent risk factor for SCO in patients with DM (OR, 1.175; P=0.014), while glycemic control was not. The use of medication did not affect the SCO, but the renin-angiotensin system inhibitors showed protective effects against acute cardiac injury (OR, 0.048; P=0.045).

Conclusion

The COVID-19 patients with DM had higher severity and resulted in SCO. Intensive and aggressive monitoring of COVID-19 clinical outcomes in DM group, especially in elderly patients is warranted.

Citations

Citations to this article as recorded by  
  • Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
    Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Severity of Symptoms and Mortality in Diabetic Patients with COVID- 19 Infection. Review
    Zahraa ALBasry, Abeer Abdulhadi Rashid, Shaymaa Hasan Abbas
    Al Mustansiriyah Journal of Pharmaceutical Sciences.2023; 23(1): 91.     CrossRef
  • Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
    Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
    Diabetologia.2023; 66(8): 1395.     CrossRef
  • COVID-19 and Cardiovascular Comorbidities
    Dirk Müller-Wieland, Nikolaus Marx, Michael Dreher, Katharina Fritzen, Oliver Schnell
    Experimental and Clinical Endocrinology & Diabetes.2022; 130(03): 178.     CrossRef
  • Prevalence and impact of diabetes in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
    Sian A. Bradley, Maciej Banach, Negman Alvarado, Ivica Smokovski, Sonu M. M. Bhaskar
    Journal of Diabetes.2022; 14(2): 144.     CrossRef
  • Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis
    Adithan Ganesh, Michael D. Randall
    British Journal of Clinical Pharmacology.2022; 88(6): 2642.     CrossRef
  • Cardioprotective effect of extracellular vesicles derived from ticagrelor-pretreated cardiomyocyte on hyperglycemic cardiomyocytes through alleviation of oxidative and endoplasmic reticulum stress
    Ceylan Verda Bitirim, Zeynep Busra Ozer, Dunya Aydos, Kardelen Genc, Seyma Demirsoy, Kamil Can Akcali, Belma Turan
    Scientific Reports.2022;[Epub]     CrossRef
  • Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis
    Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
    Endocrinology, Diabetes & Metabolism.2022;[Epub]     CrossRef
  • Glycated Albumin and Glycated Albumin/HbA1c Predict the Progression of Coronavirus Disease 2019 from Mild to Severe Disease in Korean Patients with Type 2 Diabetes
    Jeongseon Yoo, Youngah Choi, Shin Ae Park, Ji Yeon Seo, Chul Woo Ahn, Jaehyun Han
    Journal of Clinical Medicine.2022; 11(9): 2327.     CrossRef
  • Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
    Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
    Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
    Journal of the American Heart Association.2022;[Epub]     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2022; 11: 729.     CrossRef
  • Evaluating the effect of COVID-19 on quality measures of patients with type 2 diabetes in two family nurse practitioner–owned clinics
    Wendy L. Wright, Patricia A. White, Meredith Welsh, Kelly Cutting
    Journal of the American Association of Nurse Practitioners.2022; 34(9): 1090.     CrossRef
  • Early glycaemic variability increases 28-day mortality and prolongs intensive care unit stay in critically ill patients with pneumonia
    Seong Ho Kim, Ji Young Kim, Eun Song Kim, Il Rae Park, Eun Yeong Ha, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
    Annals of Medicine.2022; 54(1): 2724.     CrossRef
  • Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection
    Iris Louise N. Cabbab, Rafael Vincent M. Manalo
    Virus Research.2021; 291: 198190.     CrossRef
  • The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis
    Jiuyang Xu, Yaqun Teng, Lianhan Shang, Xiaoying Gu, Guohui Fan, Yijun Chen, Ran Tian, Shuyang Zhang, Bin Cao
    Clinical Infectious Diseases.2021; 72(11): e901.     CrossRef
  • Diabetes predicts severity of COVID‐19 infection in a retrospective cohort: A mediatory role of the inflammatory biomarker C‐reactive protein
    Huilin Koh, Angela Mei Chung Moh, Ester Yeoh, Yi Lin, Serena Kiat Mun Low, Say Tat Ooi, Seng Kiong Tan, Jaime Hui Xian Lin, Caroline Wei Shan Hoong
    Journal of Medical Virology.2021; 93(5): 3023.     CrossRef
  • Susceptibility for Some Infectious Diseases in Patients With Diabetes: The Key Role of Glycemia
    Jesús Chávez-Reyes, Carlos E. Escárcega-González, Erika Chavira-Suárez, Angel León-Buitimea, Priscila Vázquez-León, José R. Morones-Ramírez, Carlos M. Villalón, Andrés Quintanar-Stephano, Bruno A. Marichal-Cancino
    Frontiers in Public Health.2021;[Epub]     CrossRef
  • Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis
    Giovanni Corona, Alessandro Pizzocaro, Walter Vena, Giulia Rastrelli, Federico Semeraro, Andrea M Isidori, Rosario Pivonello, Andrea Salonia, Alessandra Sforza, Mario Maggi
    Reviews in Endocrine and Metabolic Disorders.2021; 22(2): 275.     CrossRef
  • COVID-19 and diabetes: Analysis of the scientific production indexed in Scopus
    Ibraín Enrique Corrales-Reyes, Frank Hernández-García, Christian R. Mejia
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(3): 765.     CrossRef
  • Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis
    Halla Kaminska, Lukasz Szarpak, Dariusz Kosior, Wojciech Wieczorek, Agnieszka Szarpak, Mahdi Al-Jeabory, Wladyslaw Gawel, Aleksandra Gasecka, Milosz J. Jaguszewski, Przemyslawa Jarosz-Chobot
    Acta Diabetologica.2021; 58(8): 1101.     CrossRef
  • Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis
    Sabrina Schlesinger, Manuela Neuenschwander, Alexander Lang, Kalliopi Pafili, Oliver Kuss, Christian Herder, Michael Roden
    Diabetologia.2021; 64(7): 1480.     CrossRef
  • Evolution of a Cohort of COVID-19 Infection Suspects Followed-Up from Primary Health Care
    Valle Coronado-Vázquez, Maria del Valle Ramírez-Durán, Juan Gómez-Salgado, María Silvia Dorado-Rabaneda, Elena Benito-Alonso, Marina Holgado-Juan, Cristina Bronchalo-González
    Journal of Personalized Medicine.2021; 11(6): 459.     CrossRef
  • Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
    Juan P. Frias, Enzo Bonora, Luis Nevárez Ruiz, Stanley H. Hsia, Heike Jung, Sohini Raha, David A. Cox, M. Angelyn Bethel, Manige Konig
    Diabetes, Obesity and Metabolism.2021; 23(10): 2279.     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
    Jordan Loader, Erik Lampa, Stefan Gustafsson, Thomas Cars, Johan Sundström
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Predictive value of HbA1c for in-hospital adverse prognosis in COVID-19: A systematic review and meta-analysis
    Zheng Zhu, Yaqian Mao, Gang Chen
    Primary Care Diabetes.2021; 15(6): 910.     CrossRef
  • High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
    Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 800.     CrossRef
  • COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
    Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
  • A Systematic Review and Meta-analysis of Diabetes Associated Mortality in Patients with COVID-19
    Puneeta Gupta, Meeta Gupta, Neena KAtoch, Ketan Garg, Bhawna Garg
    International Journal of Endocrinology and Metabolism.2021;[Epub]     CrossRef
  • Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study
    Jennifer E. Nyland, Nazia T. Raja-Khan, Kerstin Bettermann, Philippe A. Haouzi, Douglas L. Leslie, Jennifer L. Kraschnewski, Leslie J. Parent, Patricia Sue Grigson
    Diabetes.2021; 70(12): 2903.     CrossRef
  • Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis
    Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Response: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349–53)
    Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
    Diabetes & Metabolism Journal.2020; 44(3): 484.     CrossRef
  • Diabetes Mellitus is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis
    Luxiang Shang, Mengjiao Shao, Qilong Guo, Jia Shi, Yang Zhao, Jiasuoer Xiaokereti, Baopeng Tang
    Archives of Medical Research.2020; 51(7): 700.     CrossRef
  • Clinical Characteristics and Mortality Predictors of COVID-19 Patients Hospitalized at Nationally-Designated Treatment Hospitals
    Seong-Su Moon, Kwan Lee, Jungi Park, Seongcheol Yun, Yun Sik Lee, Dong Seok Lee
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Mortality Rate and Predictors of Mortality in Hospitalized COVID-19 Patients with Diabetes
    Dilaram Acharya, Kwan Lee, Dong Seok Lee, Yun Sik Lee, Seong-Su Moon
    Healthcare.2020; 8(3): 338.     CrossRef
  • Letter: The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study (Diabetes Metab J 2020;44:405–13)
    So-Yeon Kim, Kyung-Soo Kim
    Diabetes & Metabolism Journal.2020; 44(4): 621.     CrossRef
  • Response: The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study (Diabetes Metab J 2020;44:405–13)
    Seung Min Chung, June Hong Ahn, Jun Sung Moon
    Diabetes & Metabolism Journal.2020; 44(4): 625.     CrossRef
  • The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea
    Mi Kyung Kim, Jae-Han Jeon, Sung-Woo Kim, Jun Sung Moon, Nan Hee Cho, Eugene Han, Ji Hong You, Ji Yeon Lee, Miri Hyun, Jae Seok Park, Yong Shik Kwon, Yeon-Kyung Choi, Ki Tae Kwon, Shin Yup Lee, Eon Ju Jeon, Jin-Woo Kim, Hyo-Lim Hong, Hyun Hee Kwon, Chi Yo
    Diabetes & Metabolism Journal.2020; 44(4): 602.     CrossRef
  • Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study
    Min Cheol Chang, Jong-Moon Hwang, Jae-Han Jeon, Sang Gyu Kwak, Donghwi Park, Jun Sung Moon
    Endocrinology and Metabolism.2020; 35(3): 595.     CrossRef
  • Diabetes Mellitus and COVID-19
    Jeong Hyun Park
    The Journal of Korean Diabetes.2020; 21(3): 116.     CrossRef
  • Management of Diabetes in Coronavirus Disease 2019: Prognosis and Practical Issues
    Hye Soon Kim
    The Journal of Korean Diabetes.2020; 21(3): 120.     CrossRef
  • Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study
    Sun Joon Moon, Eun-Jung Rhee, Jin-Hyung Jung, Kyung-Do Han, Sung-Rae Kim, Won-Young Lee, Kun-Ho Yoon
    Diabetes & Metabolism Journal.2020; 44(5): 737.     CrossRef
  • Adverse impact of renin–angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study
    Jeong-Hoon Lim, Jang-Hee Cho, Yena Jeon, Ji Hye Kim, Ga Young Lee, Soojee Jeon, Hee Won Noh, Yong-Hoon Lee, Jaehee Lee, Hyun-Ha Chang, Hee-Yeon Jung, Ji-Young Choi, Sun-Hee Park, Chan-Duck Kim, Yong-Lim Kim, Shin-Woo Kim
    Scientific Reports.2020;[Epub]     CrossRef
  • Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective
    Junghyun Noh, Hyun-Ha Chang, In-Kyung Jeong, Kun Ho Yoon
    Diabetes & Metabolism Journal.2020; 44(3): 372.     CrossRef
  • Diabetes and COVID-19: Global and regional perspectives
    In-Kyung Jeong, Kun Ho Yoon, Moon Kyu Lee
    Diabetes Research and Clinical Practice.2020; 166: 108303.     CrossRef
Special Editorial
COVID-19
The Outbreak of COVID-19 and Diabetes in Korea: “We Will Find a Way as We Have Always Done”
Kyu Chang Won, Kun Ho Yoon
Diabetes Metab J. 2020;44(2):211-212.   Published online April 23, 2020
DOI: https://doi.org/10.4093/dmj.2020.0092
  • 4,229 View
  • 72 Download
  • 3 Web of Science
  • 3 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
    Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
    Diabetes & Metabolism Journal.2021; 45(2): 251.     CrossRef
  • Dissection of non-pharmaceutical interventions implemented by Iran, South Korea, and Turkey in the fight against COVID-19 pandemic
    Mohammad Keykhaei, Sogol Koolaji, Esmaeil Mohammadi, Reyhaneh Kalantar, Sahar Saeedi Moghaddam, Arya Aminorroaya, Shaghayegh Zokaei, Sina Azadnajafabad, Negar Rezaei, Erfan Ghasemi, Nazila Rezaei, Rosa Haghshenas, Yosef Farzi, Sina Rashedi, Bagher Larijan
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1919.     CrossRef
  • Diabetes and COVID-19: Global and regional perspectives
    In-Kyung Jeong, Kun Ho Yoon, Moon Kyu Lee
    Diabetes Research and Clinical Practice.2020; 166: 108303.     CrossRef
Brief Report
Complications
Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports
Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
Diabetes Metab J. 2020;44(2):349-353.   Published online April 23, 2020
DOI: https://doi.org/10.4093/dmj.2020.0091
  • 8,406 View
  • 182 Download
  • 65 Web of Science
  • 71 Crossref
AbstractAbstract PDFPubReader   

Since the first case was contracted by coronavirus disease-19 (COVID-19) in Daegu, Korea in February 2020, about 6,800 cases and 130 deaths have been reported on April 9, 2020. Recent studies have reported that patients with diabetes showed higher mortality and they had a worse prognosis than the group without diabetes. In poorly controlled patients with diabetes, acute hyperglycemic crises such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) also might be precipitated by COVID-19. Thus, intensive monitoring and aggressive supportive care should be needed to inadequately controlled patients with diabetes and COVID-19 infection. Here, we report two cases of severe COVID-19 patients with acute hyperglycemic crises in Korea.

Citations

Citations to this article as recorded by  
  • Clinical Characteristics and Predictors of Mortality in Obese African-Americans with COVID-19: a Single-Center Retrospective Study
    Pavani Reddy Garlapati, Suneet Kumar, Meet Patel, Bidyut Sarker, Benjamin Tiongson, Sreedhar Adapa, Sohail Abdul Salim, Mark K. Adler, Vijay Reddy Gayam
    Journal of Racial and Ethnic Health Disparities.2023; 10(1): 160.     CrossRef
  • Diabetes and the COVID-19 pandemic
    Kamlesh Khunti, Jonathan Valabhji, Shivani Misra
    Diabetologia.2023; 66(2): 255.     CrossRef
  • Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
    Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • COVID‐19 associated ketosis and diabetic ketoacidosis: A rapid review
    Tharun T. Alamuri, Sandhya Mahesh, Kevin Dell'Aquila, Taylor Jan Leong, Rebecca Jennings, Tim Q. Duong
    Diabetes, Obesity and Metabolism.2023; 25(7): 1785.     CrossRef
  • Risks associated with acute pancreatitis (AP) with diabetic ketoacidosis (DKA) in COVID-19 patients: a literature review
    Sundru Manjulata Devi, Annapurna Pamreddy, Venkata Ramana Narendra
    Journal of Diabetes & Metabolic Disorders.2023; 22(1): 135.     CrossRef
  • A Review of Hyperglycemia in COVID-19
    Maryam Zahedi, Saba Kordrostami, Mohammadreza Kalantarhormozi, Marziyeh Bagheri
    Cureus.2023;[Epub]     CrossRef
  • A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19
    Benjamin C. T. Field, Yue Ruan, Kinga A. Várnai, Jim Davies, Robert E. J. Ryder, Rajiv Gandhi, Sophie Harris, Dinesh Nagi, Dipesh Patel, Punith Kempegowda, Sarah H. Wild, Emma G. Wilmot, Kamlesh Khunti, Rustam Rea, Parth Narendran
    Diabetes, Obesity and Metabolism.2023; 25(7): 2012.     CrossRef
  • Diabetic Ketoacidosis in COVID-19 Patients: Clinical Characteristics and Outcomes – A Retrospective Study in a Single Tertiary Care Hospital, Dubai, United Arab Emirates
    Hana AL Sughaiyer, Abeer AL Haj, Samia Murad Ibrahim Abdulrahman
    Dubai Diabetes and Endocrinology Journal.2023; 29(2): 107.     CrossRef
  • COVID-19 and diabetes
    Artur Furga
    Probacja.2023; 3: 235.     CrossRef
  • COVID-19 SALGININDA DİYABET YÖNETİMİ VE HEMŞİRENİN ROLÜ
    Dilek BÜYÜKKAYA BESEN, Merve DERVİŞOĞLU
    Gazi Sağlık Bilimleri Dergisi.2022; 7(2): 78.     CrossRef
  • Diabetic ketoacidosis and COVID-19: what have we learned so far?
    Caio Oliveira de Sá-Ferreira, Camila Helena Macedo da Costa, João Campos Wiltgen Guimarães, Nathasha Souza Sampaio, Leticia de Moraes Lopes Silva, Larissa Paula de Mascarenhas, Nicollas Garcia Rodrigues, Talita Labonia dos Santos, Solange Campos, Esther C
    American Journal of Physiology-Endocrinology and Metabolism.2022; 322(1): E44.     CrossRef
  • COVID-19 and hyperglycaemic emergencies: perspectives from a developing country
    Raisa Bhikoo, Marli Conradie-Smit, Gerhard Van Wyk, Sa’ad Lahri, Elizabeth Du Plessis, Jaco Cilliers, Susan Hugo, Ankia Coetzee
    Journal of Endocrinology, Metabolism and Diabetes of South Africa.2022; 27(1): 42.     CrossRef
  • Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients
    Amr Shaaban Hanafy, Waseem M. Seleem, Hany A. Elkattawy
    Clinical and Experimental Medicine.2022;[Epub]     CrossRef
  • The COVID-19-diabetes mellitus molecular tetrahedron
    Mehdi Mahmudpour, Katayoun Vahdat, Mohsen Keshavarz, Iraj Nabipour
    Molecular Biology Reports.2022; 49(5): 4013.     CrossRef
  • Diabetes and COVID-19; A Bidirectional Interplay
    Paraskevi Kazakou, Vaia Lambadiari, Ignatios Ikonomidis, Aikaterini Kountouri, Georgios Panagopoulos, Stavros Athanasopoulos, Eleni Korompoki, Ioannis Kalomenidis, Meletios A. Dimopoulos, Asimina Mitrakou
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
    Qin Ning, Di Wu, Xiaojing Wang, Dong Xi, Tao Chen, Guang Chen, Hongwu Wang, Huiling Lu, Ming Wang, Lin Zhu, Junjian Hu, Tingting Liu, Ke Ma, Meifang Han, Xiaoping Luo
    Signal Transduction and Targeted Therapy.2022;[Epub]     CrossRef
  • Challenges in hyperglycemia management in critically ill patients with COVID-19
    Rajesh Kethireddy, Darshan Gandhi, Asim Kichloo, Love Patel
    World Journal of Critical Care Medicine.2022; 11(4): 219.     CrossRef
  • New-Onset and Persistent Insulin-Dependent Diabetes in Patients With COVID-19: A Peruvian Experience
    Anthony Ramos-Yataco, Emanuel A Salcedo Davila, Kelly Meza, Inga Harbuz-Miller
    Cureus.2022;[Epub]     CrossRef
  • Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
    Cristina Rey-Reñones, Sara Martinez-Torres, Francisco M. Martín-Luján, Carles Pericas, Ana Redondo, Carles Vilaplana-Carnerero, Angela Dominguez, María Grau
    Biomedicines.2022; 10(9): 2089.     CrossRef
  • SARS-CoV-2 Infections, Impaired Tissue, and Metabolic Health: Pathophysiology and Potential Therapeutics
    Shailendra Pratap Singh, Aayushi Bhatnagar, Sujeet Kumar Singh, Sanjib K. Patra, Navjot Kanwar, Abhinav Kanwal, Salomon Amar, Ranata Manna
    Mini-Reviews in Medicinal Chemistry.2022; 22(16): 2102.     CrossRef
  • Collateral damage due to COVID-19
    Farhan Fazal, Nitin Gupta, Wasim Khot, Yogiraj Ray
    Tropical Doctor.2021; 51(1): 126.     CrossRef
  • Diabetic emergencies during the COVID‐19 pandemic: A case–control study
    M. S. B. Huda, S. Shaho, B. Trivedi, G. Fraterrigo, L. Chandrarajan, P. Zolfaghari, T. M. Dovey, C. G. Garrett, T. A Chowdhury
    Diabetic Medicine.2021;[Epub]     CrossRef
  • Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors
    Rebecca J. Vitale, Yannis K. Valtis, Marie E. McDonnell, Nadine E. Palermo, Naomi D.L. Fisher
    AACE Clinical Case Reports.2021; 7(1): 10.     CrossRef
  • Outcomes and Healthcare Provider Perceptions of Real-Time Continuous Glucose Monitoring (rtCGM) in Patients With Diabetes and COVID-19 Admitted to the ICU
    Kenneth W. Chow, Danielle J. Kelly, Mary C. Rieff, Patricia A. Skala, Igor Kravets, Marina M. Charitou, Eric J. Morley, Rajarsi Gupta, Joshua D. Miller
    Journal of Diabetes Science and Technology.2021; 15(3): 607.     CrossRef
  • Diabetic ketoacidosis presented with COVID-19 infection: A rare case report
    Deniz Çekiç, Selçuk Yaylacı, Sümeyye Çekiç, Kubilay İşsever, Hamad Dheir, Havva Kocayiğit, Mehmet Halil Öztürk, Oğuz Karabay
    Journal of Clinical Medicine of Kazakhstan.2021; 18(1): 79.     CrossRef
  • Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
    Hee-Sung Kim, Minseok Kang, Gilwon Kang
    BMC Infectious Diseases.2021;[Epub]     CrossRef
  • Increased Incidence of Pediatric Diabetic Ketoacidosis After COVID-19: A Two-Center Retrospective Study in Korea
    Min Jeong Han, Jun Ho Heo
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 783.     CrossRef
  • Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications
    Andrey Santos, Daniéla Oliveira Magro, Rosana Evangelista-Poderoso, Mario José Abdalla Saad
    Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
  • Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins’ Mimicry of Human Protein Interactions
    Hale Yapici-Eser, Yunus Emre Koroglu, Ozgur Oztop-Cakmak, Ozlem Keskin, Attila Gursoy, Yasemin Gursoy-Ozdemir
    Frontiers in Human Neuroscience.2021;[Epub]     CrossRef
  • COVID-19 and Diabetic Ketoacidosis: Report of Eight Cases
    Balraj Singh, Prem Patel , Parminder Kaur , Nicole Majachani, Michael Maroules
    Cureus.2021;[Epub]     CrossRef
  • Machine Learning Applied to Clinical Laboratory Data in Spain for COVID-19 Outcome Prediction: Model Development and Validation
    Juan L Domínguez-Olmedo, Álvaro Gragera-Martínez, Jacinto Mata, Victoria Pachón Álvarez
    Journal of Medical Internet Research.2021; 23(4): e26211.     CrossRef
  • Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
    Ines Bilic Curcic, Maja Cigrovski Berkovic, Tomislav Kizivat, Silvija Canecki Varzic, Robert Smolic, Martina Smolic
    World Journal of Diabetes.2021; 12(6): 780.     CrossRef
  • COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
    Cyril P. Landstra, Eelco J. P. de Koning
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
    James R. Gavin, Clifford J. Bailey
    Diabetes Technology & Therapeutics.2021; 23(S3): S-19.     CrossRef
  • Evaluation of Characteristics and Outcomes for Patients with Diabetic Ketoacidosis (DKA) With and Without COVID-19 in Elmhurst Queens During Similar Three-Month Periods in 2019 and 2020
    Urja Patel, Linda Deluxe, Carlos Salama, Aaron Ross Jimenez, Adrian Whiting, Cedrick Lubin, Nancy Tarlin
    Cureus.2021;[Epub]     CrossRef
  • Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study
    Shivani Misra, Emma Barron, Eszter Vamos, Stephen Thomas, Ketan Dhatariya, Partha Kar, Bob Young, Kamlesh Khunti, Jonathan Valabhji
    The Lancet Diabetes & Endocrinology.2021; 9(10): 671.     CrossRef
  • Diabetes mellitus and COVID-19: Understanding the association in light of current evidence
    Saikat Sen, Raja Chakraborty, Pratap Kalita, Manash Pratim Pathak
    World Journal of Clinical Cases.2021; 9(28): 8327.     CrossRef
  • Follow-Up Study of the Cardiopulmonary and Psychological Outcomes of COVID-19 Survivors Six Months After Discharge in Sichuan, China
    Shuiping Dai, Bennan Zhao, Dafeng Liu, Yongzhao Zhou, Yaling Liu, Lijuan Lan, Yalun Li, Wenxin Luo, Yilan Zeng, Weimin Li
    International Journal of General Medicine.2021; Volume 14: 7207.     CrossRef
  • Diabetic ketoacidosis in patients with SARS-CoV-2: a systematic review and meta-analysis
    Saad Alhumaid, Abbas Al Mutair, Zainab Al Alawi, Ali A. Rabaan, Mohammed A. Alomari, Sadiq A. Al Salman, Ahmed S. Al-Alawi, Mohammed H. Al Hassan, Hesham Alhamad, Mustafa A. Al-kamees, Fawzi M. Almousa, Hani N. Mufti, Ali M. Alwesabai, Kuldeep Dhama, Jaff
    Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
  • In-hospital clinical complications of COVID-19: a brief overview
    Kevin John John, Jemimah Nayar, Ajay Kumar Mishra, Vijairam Selvaraj, Mohammad Saud Khan, Amos Lal
    Future Virology.2021; 16(11): 717.     CrossRef
  • Combined Hyperglycemic Hyperosmolar Syndrome and Diabetic Ketoacidosis Associated with COVID-19 in a Pediatric Patient
    Yu Shan Tseng, Bradley Tilford, Usha Sethuraman, Katherine Cashen, Mehmet Doganay
    Case Reports in Critical Care.2021; 2021: 1.     CrossRef
  • Toddler With New Onset Diabetes and Atypical Hemolytic-Uremic Syndrome in the Setting of COVID-19
    Faraz Alizadeh, Amanda O’Halloran, Areej Alghamdi, Charlotte Chen, Maria Trissal, Avram Traum, Danielle DeCourcey
    Pediatrics.2021;[Epub]     CrossRef
  • A Complicated Case of COVID-19 and Hyperglycemic Hyperosmolar Syndrome in an Adolescent Male
    Anisha Gohil, Stefan Malin, Kamal Abulebda, Tamara S. Hannon
    Hormone Research in Paediatrics.2021; 94(1-2): 71.     CrossRef
  • COVID-19 in People with Diabetes: Perspectives from Saudi Arabia
    Asirvatham Alwin Robert, Mohamed Abdulaziz Al Dawish
    Current Diabetes Reviews.2021;[Epub]     CrossRef
  • A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock
    Hong Nyun Kim, Jang Hoon Lee, Hun Sik Park, Dong Heon Yang, Se Yong Jang, Myung Hwan Bae, Yongkeun Cho, Shung Chull Chae, Yong-Hoon Lee
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature
    Rimesh Pal, Mainak Banerjee, Urmila Yadav, Sukrita Bhattacharjee
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 1563.     CrossRef
  • Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations
    Nadine E Palermo, Archana R Sadhu, Marie E McDonnell
    The Journal of Clinical Endocrinology & Metabolism.2020; 105(8): 2819.     CrossRef
  • A Case of Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State in a Patient With COVID-19
    Shemitha Rafique, Fahad W Ahmed
    Cureus.2020;[Epub]     CrossRef
  • COVID’s Razor: RAS Imbalance, the Common Denominator Across Disparate, Unexpected Aspects of COVID-19


    Maureen Czick, Christine Shapter, Robert Shapter
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 3169.     CrossRef
  • Letter: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349–53)
    Ja Young Jeon
    Diabetes & Metabolism Journal.2020; 44(3): 480.     CrossRef
  • COVID-19 in people with diabetes: understanding the reasons for worse outcomes
    Matteo Apicella, Maria Cristina Campopiano, Michele Mantuano, Laura Mazoni, Alberto Coppelli, Stefano Del Prato
    The Lancet Diabetes & Endocrinology.2020; 8(9): 782.     CrossRef
  • Diabetes and COVID-19: Global and regional perspectives
    In-Kyung Jeong, Kun Ho Yoon, Moon Kyu Lee
    Diabetes Research and Clinical Practice.2020; 166: 108303.     CrossRef
  • Hyperglycemia, Hypertriglyceridemia, and Acute Pancreatitis in COVID-19 Infection
    Chiranjeevi Gadiparthi, Mehak Bassi, Balaji Yegneswaran, Sammy Ho, Capecomorin S. Pitchumoni
    Pancreas.2020; 49(7): e62.     CrossRef
  • Response: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349–53)
    Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
    Diabetes & Metabolism Journal.2020; 44(3): 484.     CrossRef
  • Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature
    Pavan Kumar Reddy, Mohammad Shafi Kuchay, Yatin Mehta, Sunil Kumar Mishra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(5): 1459.     CrossRef
  • COVID-19 and diabetes: What have we learned so far?
    Nida Taher, Mohammed SB Huda, Tahseen A Chowdhury
    Clinical Medicine.2020; 20(4): e87.     CrossRef
  • High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing
    Fatih Yesildal, Ferruh Kemal Isman
    Turkish Journal of Biochemistry.2020; 45(5): 491.     CrossRef
  • Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective
    Junghyun Noh, Hyun-Ha Chang, In-Kyung Jeong, Kun Ho Yoon
    Diabetes & Metabolism Journal.2020; 44(3): 372.     CrossRef
  • Practical considerations for pregnant women with diabetes and severe acute respiratory syndrome coronavirus 2 infection
    Glenn P. Boyles, Stephen Thung, Steven G. Gabbe, Mark B. Landon, Maged M. Costantine
    American Journal of Obstetrics & Gynecology MFM.2020; 2(4): 100210.     CrossRef
  • Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series
    Eleni Armeni, Umaira Aziz, Sulmaaz Qamar, Sadia Nasir, Chidambaram Nethaji, Rupert Negus, Nicholas Murch, Huw Clarke Beynon, Pierre Bouloux, Miranda Rosenthal, Sidrah Khan, Ahmed Yousseif, Ravi Menon, Efthimia Karra
    The Lancet Diabetes & Endocrinology.2020; 8(8): 660.     CrossRef
  • Development of a tablet PC-based portable device for colorimetric determination of assays including COVID-19 and other pathogenic microorganisms
    Woo Sik Yoo, Hyung Soo Han, Jung Gon Kim, Kitaek Kang, Hyo-Sung Jeon, Jin-Young Moon, Hyeonmi Park
    RSC Advances.2020; 10(54): 32946.     CrossRef
  • Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation
    Akhil Vaid, Sulaiman Somani, Adam J Russak, Jessica K De Freitas, Fayzan F Chaudhry, Ishan Paranjpe, Kipp W Johnson, Samuel J Lee, Riccardo Miotto, Felix Richter, Shan Zhao, Noam D Beckmann, Nidhi Naik, Arash Kia, Prem Timsina, Anuradha Lala, Manish Paran
    Journal of Medical Internet Research.2020; 22(11): e24018.     CrossRef
  • COVID-19: the endocrine opportunity in a pandemic
    Subhankar Chatterjee, Ritwik Ghosh, Payel Biswas, Souvik Dubey, Rishi T. Guria, Chandra B. Sharma, Sanjay Kalra
    Minerva Endocrinologica.2020;[Epub]     CrossRef
  • Management of Diabetes in Coronavirus Disease 2019: Prognosis and Practical Issues
    Hye Soon Kim
    The Journal of Korean Diabetes.2020; 21(3): 120.     CrossRef
  • Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19
    Mohammad Shafi Kuchay, Pavan Kumar Reddy, Sakshi Gagneja, Anu Mathew, Sunil Kumar Mishra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2039.     CrossRef
  • Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: Case series
    Ibrahim Alsadhan, Shahad Alruwashid, Maram Alhamad, Sarah Alajmi, Sara Alshehri, Eman Alfadhli, Aishah Ekhzaimy
    Current Therapeutic Research.2020; 93: 100609.     CrossRef
  • Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients
    F.-J. Prado-Galbarro, C. Sanchez-Piedra, A.E. Gamiño-Arroyo, C. Cruz-Cruz
    Public Health.2020; 189: 66.     CrossRef
  • SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in β Cells
    Katie C. Coate, Jeeyeon Cha, Shristi Shrestha, Wenliang Wang, Luciana Mateus Gonçalves, Joana Almaça, Meghan E. Kapp, Maria Fasolino, Ashleigh Morgan, Chunhua Dai, Diane C. Saunders, Rita Bottino, Radhika Aramandla, Regina Jenkins, Roland Stein, Klaus H.
    Cell Metabolism.2020; 32(6): 1028.     CrossRef
  • Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps
    Amisha Wallia, Grace Prince, Emilie Touma, Malek El Muayed, Jane Jeffrie Seley
    Current Diabetes Reports.2020;[Epub]     CrossRef
  • Recovery From Acute Kidney Injury With Diabetic Ketoacidosis Following SARS-CoV-2 Infection: A Case Report and Literature Review
    Chang Xu, Umer Zia
    Cureus.2020;[Epub]     CrossRef
  • The Outbreak of COVID-19 and Diabetes in Korea: “We Will Find a Way as We Have Always Done”
    Kyu Chang Won, Kun Ho Yoon
    Diabetes & Metabolism Journal.2020; 44(2): 211.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal